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Abstract 
Epilepsy and migraine are two distinct paroxysmal neurological disorders yet both 
disorders overlap in multiple aspects. The objective of this thesis was to study two of 
the phenomena shared by these disorders, namely photosensitivity and cortical hyper-
excitability. For this purpose, I chose the multifocal objective pupillographic perimetry 
device (mfPOP) to study the largely subcortical part of the visual pathway responsible 
for the pupillary response. The main objectives were first, to examine whether the 
objective perimetry results differed from the general population in these two disorders, 
second to explore whether there were differences between sub-types of the disorders 
and, third, to estimate the safety and tolerability of the mfPOP protocols that involve 
light stimulation. We also examined the effects of treatments that might affect brain 
excitability. I then went further and analysed electroencephalograms (EEG) recorded 
from epilepsy subjects looking at changes in the alpha rhythm entrainment in response 
to photic stimulation as an added indicator of cortical excitability. These effects were 
correlated with the mfPOP results. 
Regarding photosensitivity, I found that the mfPOP device appeared to be safe when 
used in migraine subjects, even when a method designed specifically designed to 
stimulate the melanopsin containing retinal ganglion cells was used: these cells have 
been implicated in the mechanism of exacerbation of migraine headaches by light. 
Safety was also supported clinically and objectively for epilepsy patients by using 
EEGs and finding them to be clear of epileptiform activities during mfPOP testing. 
7 
Regarding cortical excitability, I found that this phenomena did indeed affect the pupil 
derived perimetry responses, with the responses being increased post-ictally and inter-
ictally in epilepsy patients while being normal in the inter-ictal period in migraineurs 
and decreased after migraine attacks. These changes were reversed by two distinct 
classes of medication, anti-epileptics in epilepsy and triptans in migraine patients. Some 
disease-specific differences in the location of visual field defects were observed, 
especially for response sensitivity. Disease dependent changes in mfPOP response 
delays were observed, which were more generalised across the visual fields more than 
the sensitivity changes. 
These findings were further supported by demonstrating that the alpha entrainment was 
more pronounced in epilepsy patients than the normal population and that it was also 
affected by medication use. These findings were consistent with the fact that both 
disorders have been shown to demonstrate an increase in cortical excitability in 
between attacks, this increase being more pronounced in epilepsy subjects. Medication 
consumption has a dampening effect on this excitability. During a migraine attack, this 
excitability is believed to transition to cortical spreading depression rather than to the 
hyper-synchronous activity that characterizes epilepsy.  
These results, combined with our earlier study of Multiple Sclerosis, demonstrate that 
mfPOP is a valuable tool in studying neurological disorders especially in populations 
with motor deficits. With its safety now relatively well established it can help shed a 
light on the pathophysiology of these disorders and aid in their diagnosis.  
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1.1. Overview  
 
Epilepsy and migraine are among the most prevalent neurological conditions, and 
although they are two distinct neurological disorders characterized by transient 
paroxysmal episodes of altered brain function resulting in recurrent attacks of nervous 
system dysfunction with a return to baseline between attacks (Haut et al., 2006), both 
disorders converge in multiple aspects. It was as far back as 1906 that the coexistence 
of the two disorders  in some subjects was highlighted by Gowers  (Gowers, 1906). He 
went further to describe the occurrence of the visual, sensory and motor prodromes, and 
the associated symptoms of vertigo, pain, somnolence and delirium in both disorders. 
Since then, these similarities have been further highlighted in many studies that found 
that the presence of one disorder increases the probability of the other occurring in the 
same subject (Ottman and Lipton, 1996). Furthermore, the phenomenon of 
photosensitivity is shared by both disorders, and the underlying pathophysiology is 
attributed to altered  ion channels and ion transporters (Ryan and Ptacek, 2010). These 
changes lead to a state of cortical hyper-excitability which is critical for generating 
epileptic seizures, and is also demonstrated between migraine attacks using visual 
evoked responses (Ambrosini et al., 2003), trans-cranial magnetic stimulation (Aurora 
et al., 1999) and electroencephalogram (Nyrke et al., 1990). However, hyper-
excitability during a migraine attack is believed to transition to cortical spreading 
depression  (CSD) rather than to the hyper-synchronous activity that characterises 
epilepsy (Parisi et al., 2008). Cortical hyper-excitability is believed to be the reason 
why treatments involving antiepileptic drugs are useful in both conditions (Silberstein 
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et al., 2012, Bianchin et al., 2010, Ziemann et al., 1996). Whether this excitability 
extends to involve subcortical pathways is not yet known.  
We chose to explore changes in the pupillary response pathway in migraine and 
epilepsy because it serves as a subcortical pathway which is subject to cortical 
influence and it is part of the visual pathway which is primarily responsible for 
photosensitivity. We used the multifocal pupillary objective perimetry (mfPOP) device 
by itself or in conjunction with electroencephalography (EEG) to reach our goals. 
In this introduction I will first highlight further the similarities between epilepsy and 
migraine; second, I will explore in depth the concept of cortical excitability and, third, I 
will discuss photosensitivity, its triggers and its postulated mechanisms. Then I will 
identify how the photic drive response seen in EEGs relates to both photosensitivity and 
hyper-excitability and, finally, I will discuss multifocal methods and why I chose the 
mfPOP device to explore these phenomena and how it may increase our understanding 
of the pathophysiology of migraine and epilepsy.  
 
 
1.2. Epilepsy and migraine  
 
1.2.1.  Definitions 
 
Migraine is a recurrent headache disorder that manifests itself in attacks lasting 4–72 h. 
Typical characteristics are unilateral location, pulsating quality, moderate or severe 
intensity, aggravation by routine activity and association with nausea and/or 
photophobia and phonophobia. It is divided into two major subtypes: migraine with 
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aura and migraine without aura according to the International Classification of 
Headache Disorders third edition (CHD-3) (2004, 2013).  
Epilepsy is defined according to the International League Against Epilepsy (ILAE) as a 
disease of the brain with the possible features: (1) at least two unprovoked (or reflex) 
seizures occurring more than 24 hours apart; (2) one unprovoked (or reflex) seizure and 
a probability of further seizures similar to the general recurrence risk (at least 60%) 
after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an 
epilepsy syndrome (Fisher et al., 2014). Epilepsy can be broadly classified into two 
main types: generalized, which mainly includes idiopathic generalised epilepsy (IGE), 
and focal. IGE, is believed to have a strong underlying genetic basis, while focal 
epilepsies are mostly considered to be due to underlying focal pathology such as 
hippocampal sclerosis or an area of cortical dysgenesis (Fisher et al., 2014). 
The term migraine-triggered seizures or “migralepsy” was introduced by Lennox and 
Lennox in 1960 and describes a condition in which ophthalmic migraine is followed by 
symptoms characteristic of epilepsy (Lennox and Lennox, 1960). Although this term 
has been the object of debate, it was included in the ICHD-3 (2013). In addition, two 
other disorders that highlight the coexistence of headache and epilepsy were also 
included in the ICHD-3: they are hemicrania epileptica, and postictal headaches. 
  
1.2.2. Clinical aspects  
 
Both epilepsy and migraine are chronic diseases with episodic attacks. Interictally, both 
disorders exhibit an increased predisposition to future attacks. During attacks, both are 
clinically manifested by repeated episodes of paroxysmal events, often preceded by 
prodromes and/or auras. (Table 1) summarises the clinical aspects that are common to 
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the two disorders (Bianchin et al., 2010). In addition, occasional attacks of both 
disorders may fail to stop resulting in status epilepticus or status migrainosus.  
Epilepsy and migraine can precede or succeed each other, or even occur 
simultaneously. With respect to epilepsy the temporal relationship of headache and 
migraine occurrence is shown in (Figure 1) (Bianchin et al., 2010).  5% to 15% of 
patients with epilepsy report headaches pre-ictally. Ictal headaches are reported by less 
than 5% of patients and may reflect a true epileptic phenomenon, impairment of 
conciseness provoked by seizure leading to failure of subjects to report headaches may 
be attributed to this low prevalence. Postictal headaches occur in 10% to 50% of 
patients with epilepsy, often resembling migraines and responding to migraine 
treatments such as ergotamine derivatives or to triptans (Bianchin et al., 2010). 
Some epileptic syndromes show a strong association with migraine by history, like 
benign occipital epilepsy of childhood (Caraballo et al., 2008). Others share genetic risk 
factors involving various components of ionic channels like those of benign rolandic 
epilepsy (Clarke et al., 2009), familial occipito-temporal lobe epilepsy (Deprez et al., 
2007), and familial hemiplegic migraines (Barrett et al., 2008).  
A further similarity between the two disorders that further supports the notion of a 
sometimes shared underlying mechanism is that some antiepileptic medications are 
useful in treating both conditions, specifically sodium valproate and topiramate which 
are used as preventive medications (Silberstein et al., 2012).  
I will next discuss in details two major areas of similarity between migraine and 
epilepsy, namely cortical hyper-excitability and photo-sensitivity.  
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Table 1. Symptoms common to both migraine and epilepsy. Adapted with permission 
from (Bianchin et al., 2010) 
Symptom Migraine Epilepsy 
Systemic   
Vomiting + ± 
Nausea + ± 
Diarrhea ± − 
Headache + ± 
Visual disturbances   
Coloured circles − + 
Black and white lines + − 
Blindness ± ± 
Blurred vision + + 
Visual triggering factors + + 
Other neurologic   
Olfactory ± + 
Vertigo + ± 
Confusion ± + 
Loss of consciousness ±** + 
Impaired consciousness ± + 
Loss of memory ± + 
Post event lethargy + + 
Depersonalization ± + 
Paresthesias + + 
Hemiparesis ±** + 
Hemi-sensory loss ±** + 
Aphasia ±** + 
+ denotes presence; − denotes absence; ± denotes rarely reported  
**Present in hemiplegic migraine. 
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Figure 1. Time distribution of headache and migraine in epilepsy. Migraine and 
epilepsy are comorbid. They are bi-directional and one can precede or succeed the other 
or even occur simultaneously. Numbers represent approximate percentage range of 
headache occurring in respect of an epilepsy attack. According with seizures, headache 
can be classified as interictal, preictal, ictal, or postictal. Adapted with permission from  
(Bianchin et al., 2010). 
 
 
 
 
 
 
 
1.3.   Cortical hyper-excitability  
 
The nervous system represents a complex arrangement of highly specialised neural 
circuits which are critically dependent on healthy excitatory and inhibitory systems. 
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Excitability of cell membranes appears to be a fundamental factor in the brain’s 
susceptibility to various disorders.  Excitation is mainly facilitated by the action of 
glutamate on N-methyl-d-aspartate (NMDA), and non-NMDA receptors, while 
inhibition is mainly mediated by the action of gamma-aminobutyric acid (GABA) on 
GABAA and GABAB receptors. Abnormal reorganization of brain circuits can result in 
various neurological disorders including epilepsy and migraine (Badawy et al., 2012). 
In animal studies cortical excitability has been studied using direct current stimulation 
(DCS) where it was found that cortical neuronal depolarization is caused by anodal 
DCS at a subthreshold level, while they are hyperpolarized by cathodal DCS (Purpura 
and McMurtry, 1965). Alteration of membrane potential causes in turn alteration of 
spontaneous neuronal discharge (Purpura and McMurtry, 1965) and if the current is 
applied for a sufficient long period (10-30 minutes) after effects lasting for hours can be 
achieved (Bindman et al., 1962). changes in cyclic AMP generation are suggested to 
form the neurochemical basis of changes induced by anodal polarization (Hattori et al., 
1990) . The after-effects of DCS are suggested to be due to NMDA receptor dependent 
(Liebetanz et al., 2002). Furthermore cyclic AMP accumulation is proposed as the basis 
of changes seen in induced chronic  epilepsy animal models (Hattori et al., 1992) 
(Hattori et al., 1993) (Hattori, 1990). Also Agonists of all three major ionotropic 
glutamate receptors, quisqualate, kainate, and NMDA, were effective in inducing 
cortical spreading depression in turtles a key step in the generation of migraine aura 
(see below) (Lauritzen et al., 1988). 
  1.3.1. Migraine and cortical excitability  
 
Mechanisms involved in the generation of a migraine headache are complex and not 
fully understood. It is believed that neurotransmitter disturbances, especially calcitonin 
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gene-related peptide and serotonin (Ogilvie et al., 1998), channelopathies (like the P/Q-
type Ca2+ channel defects in familial hemiplegic migraine) (Ophoff et al., 1998), and 
cortical spreading depression with subsequent release of inflammatory mediators 
(Pietrobon, 2005) all play a role in migraine headache generation. The proposed 
cascade of events that leads to a migraine attack are summarized in (Figure 2) (Lance, 
1996). At the start of a migraine attack, visual auras may appear. They consist of a 
scotoma with a scintillating border that usually begins near the centre of vision as a 
twinkling star and then develops into an expanding half-circle that slowly expands 
across the visual field toward the periphery. Looking at the underlying mechanism of 
these scotomas, Lashley postulated in 1941 that the scotoma results from a region of 
depressed neural activity in the visual cerebral cortex and that the scintillations result 
from a bordering region of intense cortical excitation (Tfelt-Hansen, 2010). This 
depression was later found to be associated with a reduction regional cerebral blood 
flow starting at the parieto-occipital region and spreading forward at a rate of 2-3 
mm/min, corresponding to the speed of both the fortification spectra movement over 
the field of vision and the cortical spreading depression (CSD) observed by Leão in 
rabbits’ EEGs. Leão was attempting to develop a model of experimental epilepsy by 
electrically stimulating the cortical surface; instead, he found that a weak electrical 
stimulation elicited a decrease in the spontaneous activity on EEG that spread out from 
the stimulated region in all directions at a rate of 3-5 mm/min and that spontaneous 
activity recovery occurred over 5 to 10 min (Leao, 1986). Thus, CSD is a wave of 
profound depression in neural activity preceded by neuronal activation, and so it is 
believed to underlie migraine aura and to be a trigger for the headache pain in migraine 
(Grafstein, 1956).  
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Figure 2. Mechanism of migraine attack. A flow chart showing the cascades of 
events underlying the pathophysiology of migraine headaches. 
‐Brain threshold to pain: set by several factors 
‐Defects in: Genetics, magnesium deficiency, 
excitatory amino acids, sensitivity of the dopamine 
system and the hypothalamus, and vascular 
reactivity
‐Cortical hyper‐excitability: reduced threshold  to a 
variety of stimuli
‐Susceptibility to Triggers : Central and prephral 
csensetization 
‐Spreading depression of Leão: may or not be perceived as 
aura and pain. It takes 5–60 min before recovery takes place
‐Vascular changes: spreading oligaemia (2–3 mm/min) can last 
several hours and are followed by delayed hyperaemia
‐Spreading oligaemia reaches sensory motor areas of the brain:  
the patient experiences the focal neurological aura symptoms
‐The key pathways for the pain  is the trigeminovascular input 
from the meningeal vessels, which passes through dural
branches of the trigeminal nerve >> trigeminocervical complex 
>> thalamus >> sensory cortex
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The existence of cortical hyper-excitability in migraine was confirmed using visual 
evoked potentials (Lehtonen, 1974, Connolly et al., 1982) which demonstrated 
evidence of increased P100 amplitude, as well as on transcranial magnetic stimulation 
(TMS). For both motor and visual occipital cortex TMS has been used to show 
increased cortical excitability between migraine attacks. Visual hyper-excitability 
occurred when TMS stimulation was delivered over the occipital cortex, leading to the 
perception of ‘phosphenes’ (flashes of light) which were reported by the subjects 
(Aurora et al., 1999, Bohotin et al., 2003, Gunaydin et al., 2006).  Highly excitable 
neurons need to be stimulated less than depressed neurons in order to elicit either visual 
or motor responses, thus, TMS can be used to measure cortical excitability in vivo. 
Occipital cortical TMS studies reported evidence of hyper-excitability due to decreased 
inhibition, particularly in migraine with aura (Gunaydin et al., 2006, Aurora et al., 
1999). Motor hyper-excitability has been demonstrated by recording a muscle response 
in the form of a twitch using electromyography (EMG) when TMS stimuli are delivered 
over the primary motor cortex. The results of such techniques showed a pattern of 
changes in migraine similar to those seen in epilepsy, although of much smaller 
magnitude. This provides more evidence supporting an overlap between the two 
paroxysmal disorders (Badawy and Jackson, 2012). Moreover, cortical excitability 
changes were found to change dynamically with respect to migraine attack timing   
(Bohotin et al., 2003, Judit et al., 2000). 
  1.3.2. Epilepsy and cortical excitability  
 
Disturbance in the neuronal excitatory/inhibitory balance leading to the formation of 
hyper-excitable seizure networks is an important proposed mechanism underlying the 
pathophysiology of epilepsy (McCormick and Contreras, 2001). Alterations in cortical 
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excitability have been observed for 24, and even up to 48, hours before and after 
seizures. In addition, several factors have been found to alter this excitability including 
menstrual cycle, time of day, sleep and sleep deprivation, possibly explaining why 
these factors are considered to be epilepsy triggers in themselves. Epilepsy treatments 
including: antiepileptic medications irrespective of the underlying mechanism and 
target receptor, successful epilepsy surgery, vagal nerve stimulation or  thalamic deep 
brain stimulation have all shown reduction of the baseline hyper-excitability to normal 
or near normal values in patients who have become seizure-free (Badawy et al., 2012). 
The mechanism, as proved by transcranial magnetic stimulation, understood to be 
through changes in either intracortical excitability caused by GABA-controlled 
interneuronal circuits in the motor cortex or changes in motor thresholds dependent on 
ion channel conductivity (Ziemann et al., 1996). 
      1.3.3. A shared mechanism for epilepsy and 
migraine 
 
Ottoman and Lipton proposed that the comorbidity of migraine and epilepsy cannot be 
explained by genetic mechanisms alone, instead, they proposed that a state of brain 
hyper-excitability that results from genetic as well as environmental risk factors 
increases the risk of both conditions, thus leading to their comorbid association (Ottman 
and Lipton, 1996).  
An example of shared genetic mechanisms between the two disorders is familial 
hemiplegic migraine (FHM) that predisposes to both migraine and epilepsy as a result 
of alteration in ion channels responsible for cell membrane homeostasis. FHM is an 
autosomal dominant syndrome characterized by severe migraine. It arises as a result of 
mutations in genes coding for the membrane ion transport proteins CACNA1A (P/Q-
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type voltage-gated calcium channel), ATP1A2 (Na+-K+ ATPase), or SCN1A (voltage-
gated sodium channel). Mutations in all these genes can also cause generalized, and in 
some cases focal epilepsy, and are associated with the co-occurrence of FHM and 
seizures in the same family members (Barrett et al., 2008).  
 In general, many neurological episodic disorders – which include migraine and many 
types of epilepsies – are due to defects in ion channels and/or ion transport proteins that 
result in a reduced safety margin to regular stressors which in turn act as trigger factors 
that overcome homeostatic mechanisms that prevent the development of a pathological 
state (Ryan and Ptacek, 2010). (Figure 3) summarises the cellular events leading to the 
generation of an epileptic or a migraine event. A trigger is required as an initiator of an 
attack in both disorders causing glutamate release via voltage-gated Na+ channels. This 
leads to hyper-excitability resulting in the development of hypersynchronous neuronal 
discharges through the AMPA receptors leading to the generation and spread of 
epilepsy, while in migraine NMDA receptors mediate the transition of hyper-
excitability into CSD. This may explain why some antiepileptic medications do prevent 
migraine attacks whereas others, notably those acting on voltage-gated Na+ channels or 
which act via GABAergic mechanisms (e.g. phenytoin , carbamazepine, vigabatrin and 
clonazepam), do not prevent migraine attacks (Rogawski, 2012). The broad range of 
propagation rates that happens in epilepsy as opposed to the relatively quick 
propagation in migraine is due to the fact that in epilepsy the glutamate release is 
entirely a synaptic process, while in migraine a wave of neuronal and glial 
depolarization that has a well-defined rate of propagation of about 3 mm/min occurs via 
intercellular gap junctions leading to CSD (Rogawski, 2012). As CSD propagates 
glutamic acid, released during CSD, convert into c- aminobutyric acid (GABA). This 
conversion has been suggested as the possible mechanism of hyperpolarizing type of 
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inhibition at the late phase of unit activity blockade after CSD (Mesgari et al., 2015). 
Applying a low concentration of a GABAA blocker has been shown to generate spiking 
activity during the late excitability state of CSD in epileptic human brain tissues and in 
non-epileptic rat brain (Dreier et al., 2012, Mesgari et al., 2015). These Changes during 
the late hyper-excitability phase of CSD have been suggested to contribute not only to 
the pathophysiology of migraine but to epilepsy as well (Dreier et al., 2012). In 
addition, brain pathologies associated with CSD include concussion, hypoxia and 
ischemia (Somjen, 2001) all of which are associated with epilepsy. Add to that 
neocortical CSD propagate to hippocampal structures- an area involved in the most 
common type of focal epilepsy temporal lobe epilepsy- affecting the hippocampal 
function (Wernsmann et al., 2006). As addressed above, migraine and epilepsy share 
many similarities in regards to cortical excitability and thus underlying 
pathophysiological mechanisms.  
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Figure 3: cellular events in the evolution of an epileptic seizure and migraine 
attack. Highlighting the similarities and differences. In epilepsy, synaptic glutamate 
release acting through AMPA receptors is a trigger factor, and synaptic activity is 
required for propagation. In migraine, synaptic glutamate acting through NMDA 
receptors is a trigger factor. Once established, synaptic activity may no longer be 
necessary and glutamate release from glia is the predominant factor that drives the 
advancing front of spreading depression. The spreading depression wave triggers the 
release of mediators that activate the trigeminovascular system, resulting in headache 
pain. Voltage-gated Na+ channel dependence (tetrodotoxin-sensitivity) implies the 
involvement of synaptic mechanisms. CGRP, calcitonin gene-related peptide. Adapted 
with permission from (Rogawski, 2012).  
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1.4.  Photosensitivity 
 
Another important association between migraine and epilepsy is photosensitivity. I will 
outline several studies that have investigated the triggering role of photosensitivity in both 
headache and epilepsy. 
1.4.1. Migraine and photosensitivity 
 
 Factors that induce attacks in susceptible migraine individuals, alone or in combination, are  
known as migraine triggers (Zagami and Bahra, 2006). They usually precede attacks by less 
than 48 hours (Zagami and Bahra, 2006). Identifying such trigger factors is important in 
management because treatment programs emphasise awareness and avoidance (Friedman and 
De ver Dye, 2009). In a literature review of migraine triggers, visual disturbances – defined 
as flicker, glare, and eyestrain – were identified as a trigger in 27 – 75% of cases (Martin, 
2010). In general, light characteristics that can potentially cause discomfort are summarized 
as follows:  
1)  Spatial pattern. Patterns containing periodic elongated parallel lines of alternate light and 
dark stripes have been perceived as uncomfortable for migraine subjects (migraineurs) (82%) 
compared to non-migraine headache sufferers (18%) (Marcus and Soso, 1989). The pattern 
should stimulate a large portion of the visual cortex, for example by covering a substantial 
portion of the central visual field. Smooth-edged patterns are much less effective as visual 
triggers. 
2) Temporal pattern. Periodic flicker at about 3 Hz for several seconds was perceived as a 
visual stressor in 80.6% of classic migraine subjects in comparison to only 14.9% of normal 
controls (Hay et al., 1994).  
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3) Light intensity. Between attacks, migraine sufferers reported decreased light discomfort 
threshold to whole-field flashes of around 95 Lux compared to controls at 200 Lux (p< 
0.00005) (Main et al., 1997).  
4)  Light wavelength. In one study, red colour was reported as uncomfortable when 
migraineurs were asked to manipulate the colour of light falling on a passage of high contrast 
text (Chronicle and Wilkins, 1991). However, in another study results indicated that the 
migraine group had significantly lower discomfort thresholds at both low (blue) and high 
(red) wavelengths compared with tension-type headache and control groups (Main et al., 
2000). 
New insights into how light could modulate photosensitivity in migraine subjects was the 
subject of a study conducted by Noseda et al (Noseda et al., 2010) in which they examined 
the exacerbation of migraine headache by light in blind people. Six subjects had no light 
perception, either due to enucleation of the eye or to damage to the optic nerve (i.e. lacking 
input from all retinal layers) and when exposed to light, the intensity of these patients’ 
headaches was unaffected, suggesting that migraine photophobia depends on signals relayed 
from the retina to the brain via the optic nerve. On the other hand, 14 legally blind subjects 
with preserved non-image-forming pathways (i.e. capable of detecting light in the face of 
markedly deficient image-forming perception, <20/200 vision) with histological evidence of 
total loss of the outer photoreceptor layer and preservation of the inner layers, had increase in 
both migraine headache intensity and photophobia with increased ambient light despite 
degeneration of both rods and cones. These findings led the authors to speculate that the 
exacerbation must be related to a non-image forming visual pathway mediated via the 
melanopsin-containing (intrinsically photosensitive) retinal ganglion cells (Hattar et al., 
2002). Major differences between the image forming and non-forming pathways are 
summarized in (Table 2). 
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Table 2. Differential features between the classical and the melanopsin photoreceptive 
pathways. Adapted from  (Benarroch, 2011) 
Pathway Classical (image-
forming) 
Melanopsin (non-
imaging-forming) 
Photoreceptor cell Rods and cones ipRGCs 
Photo-pigment  Rhodopsin cone opsins Melanopsin 
Light sensitivity All visible wavelengths Most sensitive to blue 
wavelengths 
Response to light  Hyperpolarization Depolarization  
Receptive fields Very small Very large 
Properties Fine spatial resolution  Temporal integration of 
ambient light (irradiance) 
Main target of ganglion 
cells  
Lateral geniculate nucleus  
Superior colliculus 
Olivary pretectal nucleus 
Suprachiasmatic nucleus 
Subparaventricular zone  
Ventrolateral preoptic area 
Intrageniculate leaflet of 
the lateral geniculate 
nucleus  
Olivary pretectal nucleus  
Function  Image formation  
Pupillary light reflex 
(early and 
transient response) 
Entrainment of circadian 
clock 
Light-induced sleep 
regulation and inhibition 
of melanotonin secretion 
Pupillary light reflex 
(sustained response) 
Involvement in disease  *Rod – cone dystrophies. 
*Mitochondrial optic 
neuropathy by loss of 
RGCs and optic nerve 
atrophy e.g. Leber 
hereditary optic 
neuropathy (LHON) and 
autosomal-dominant optic 
atrophy 
Seasonal affective disorder 
Glaucoma  
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Unlike the image-forming pathway, which is generated by photo-activation of the opsin-
based photo pigments in both the rods and cones and subsequent activation of the retinal 
ganglion cells (RGCs) whose axons form the optic nerve that travel to the lateral geniculate 
nucleus, the superior colliculus, and terminate in the visual cortex, the non-image forming 
pathway is mediated by a specialized pathway originating from intrinsically photosensitive 
RGCs (ipRGCs). These ipRGCs are not only activated by input from rods and cones but also 
activated directly by light acting intrinsically via the unique photo-pigment melanopsin. 
These retinal ganglion cells are unique in their ability to transduce light into electrical energy 
(Figure 4). The axons of these Melanopsin-containing ipRGCs project via the optic nerve to 
several targets in the diencephalon and midbrain. These cells provide a major contribution to 
the afferent limb of the pupillary light reflex by sending a direct projection to the the 
suprachiasmatic nucleus, inter-geniculate leaflet, and, subsequently, the olivary pretectal 
nucleus of the midbrain; this nucleus projects to the Edinger-Westphal nucleu, which sends 
efferents to the ciliary ganglion. 
Noseda’s group went further to investigate whether the central trigemino-vascular pathway, 
which is responsible for carrying the pain signal from the dura mater to the brain, is also 
regulated by the non-image forming signals from the eyes and thus the melanopsin-
containing ipRGCs. Using single-unit recording and neural tract tracing in the rat they found 
that the axon projections of the ipRGCs and dura-sensitive neurons, i.e. activity modulated by 
light, converged in the posterior thalamus and from there they projected extensively to the 
somatosensory cortex, visual, and associative cortices, leading them to hypothesize that 
migraine pain is modulated at the level of the thalamus by retinal activation of the ipRGCs 
(Figure 5). 
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Figure 4. Visual pathways. The image forming pathway: light activates cones and rods in 
the retina which intern activate the RGCs and information is carried by the optic nerve (large 
red arrow). The non-image forming pathway is mediated by the ipRGCs, which in addition to 
being activated by rods and cones, they are intrinsically activated by light via the photo-
active pigment melanopsin (large blue arrow). In addition ipRGCs also provide input to the 
image forming pathway (small red arrow) (Matynia, 2013) 
ipRGCs = intrinsically photosensitive retinal ganglion cells, RGCs= retinal ganglion cells.  
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Figure 5. Proposed mechanism for exacerbation of migraine headache by light through 
the convergence of the photic signals from the retina and nociceptive signals from the 
meninges onto the same thalamic neurons that project to the somatosensory cortices. Red 
depicts the trigeminovascular pathway. Blue depicts visual pathway from the retina to the 
posterior thalamus. Abbreviations: RGC, retinal ganglion cells; ipRGC, intrinsically-
photosensitive retinal ganglion cells; TG, trigeminal ganglion; Sp5, spinal trigeminal nucleus; 
LP, lateral posterior nucleus; Pul, pulvinar; S1, primary somatosensory cortex; S2 secondary 
somatosensory cortex. Adapted with permission from (Noseda and Burstein, 2011) 
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In addition to being responsible for adaptation of static pupillary size to light (Kawasaki and 
Kardon, 2007), ipRGCs have also been implicated in the entrainment of the biological clock 
to the dark-light cycle and suppression of melatonin release by light (Gooley et al., 2003).  
Since 1998 when Provencio et al first identified a novel opsin from the dermal melanophore 
cells of the frog and called it melanopsin (Provencio et al., 1998). Since its subsequent 
discovery in humans (Provencio et al., 2000), several studies have highlighted the specific 
characteristics of these ipRGCs. Located in the ganglion cell layer of the retina, these cells 
have a giant somata and long, branching dendritic processes. The M1 subtype of ipRGCs 
extend their processes to the outer sublayer of the inner plexiform layer (where an “off” 
response is triggered upon the interaction with blue  – short wavelength – S cones), and the 
M2 subtype project to the inner sublayer (where the rods and red  –long wavelength  – L 
cones, and green  – medium wavelength  – M cones provide an “on” response) (Hattar et al., 
2002, Baver et al., 2008). 
The retinal area with the highest ipRGC density was found to be located around the fovea 
with peak density of 20-25 cells/mm2 (Dacey et al., 2005). Melanopsin has a peak spectral 
sensitivity at ~ 480 nm, i.e. blue/cyan light (Dacey et al., 2005). The probability of absorbing 
a photon by ipRGCs is >1 million times lower than in rods or cones for a given area of 
photostimulation (Do et al., 2009). Therefore, in order to ensure optimal melanopsin-driven 
sustained pupil responses, a bright light stimulus presented at greater than about 1 per second 
is needed (Park et al., 2011). 
New modalities of migraine treatments have emerged based on our knowledge of the 
melanopsin-containing ipRGCs, such as pharmacological manipulation of melanopsin via the 
a small molecule (opsinamide) that antagonizes melanopsin-mediated phototransduction  
(Jones et al., 2013). Even before the discovery of the ipRGCs, blocking blue wavelengths 
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using tinted lenses in children with migraine was found to reduce  frequency, duration and 
intensity of migraine attacks (Good et al., 1991). 
Therefore, the study of the pupillary response to understand the effects of ipRGC stimulation 
on migraine pathophysiology may have a role in helping to decrease the burden of this 
disorder. 
 
1.4.2. Epilepsy and photosensitivity  
 
1.4.2.1. Definitions  
 
In order to address photosensitivity in epilepsy patients I will start with some definitions.  
 Photic-induced seizures (PIS) constitute part of a larger subtype of epilepsies known 
as reflex epilepsies. They are defined as seizures provoked by visual stimulation. The 
usual stimulus is a flashing light, but it can be patterns of lines, gratings, 
checkerboards, or other configurations (Fisher et al., 2005). 
 Photosensitivity is an abnormal visual sensitivity of the brain in response to flickering 
or intermittent light sources or patterns; it is expressed in the electroencephalogram 
(EEG) as a generalized spike-and-wave discharge (photoparoxysmal response, PPR) 
(Covanis, 2005, Fisher et al., 2005, Harding, 1994).  
 
 
1.4.2.2.  Epidemiology  
 
The estimated prevalence of seizures from light stimuli is approximately 1 per 4,000 
individuals aged 5-24 years. 2% of epileptic patients have PIS but its prevalence increases up 
to 10% when patients aged 7–19 years are studied (Fisher et al., 2005). It is more common in 
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females and it is believed that there may be an important genetic component, probably 
autosomal dominant inheritance with reduced penetrance, although no major photosensitivity 
gene has yet been identified. The most common form of PIS is a generalized tonic-clonic 
convulsion (79%), followed by absence seizures (occurring in 10% of patients) and 
myoclonic seizures (occurring in 6% of patients), with focal seizures occurring in 5% (Fisher 
et al., 2005). The pathophysiology of photosensitivity is believed to be related to increased 
excitability of the occipital cortex as demonstrated by functional MRI and transcranial 
magnetic stimulation studies (Chiappa et al., 1999, Siniatchkin et al., 2007). 
1.4.2.3. Light characteristics  
 
 Seizures can be provoked by certain TV shows, movie screen images, video games, natural 
stimuli (e.g. sun on water), public displays, and many other sources. Identifying light 
characteristics that provoke PIS is of great importance. Several studies have attempted to do 
so (Covanis, 2005, Harding et al., 2005, Parra et al., 2005, Wilkins, 1995). These 
characteristics are summarised as follows:-  
1. Stripe patterns: with sharp edges, high contrast and a 50:50 duty-cycle. 
2. Flicker: at > 3 Hz, the risk is increased when the stimulus contains 5 or more parings 
of black/red or blue/red alternation (Parra et al. 2005).   
3. Checkerboard patterns are about 5 times less likely to generate PIS than patches of 
stripes that have aspect ratios of 20 or more. Sine-wave gratings are quite ineffective.  
4. Intensities of 0.2-1.5 million candlepower are in the range to trigger seizures.  
5. Frequencies of 15-25 Hz are most provocative (range is 1-65 Hz).  
6. Stimuli subtending more than a quarter of the central 10 degrees of the visual 
field; much of the visual cortex is dedicated to that part of visual space, and so 
concurrent stimulation of a large part of the cortex can be achieved by stimulating just 
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that area of visual space. Stimulating greater than 10% of the cortex is required to 
generate a PIS.  
7. Synchronous activation of both eyes increases the probability of epileptiform EEG 
by about 4-fold over a broad range of luminance.  
Combination of both of spatial and temporal stimulus aspects are required to have a 60% 
chance of inducing PIS. 
1.4.2.4. Light-emitting devices and photic induced 
seizures 
 
Recommendations on reducing the risk of seizures have been developed by agencies in the 
United Kingdom, Japan, and the International Telecommunications Union, affiliated with the 
United Nations. Guidelines were developed following several incidents.  In 1993, three 
people in the United Kingdom reported seizures while watching a television commercial for 
Golden Wonder Pot Noodle due to rapidly flashing contrast changes. This led the British 
government to respond by investigating what could be done to prevent future similar 
occurrences. The television regulatory agency introduced broadcast guidelines and has 
subsequently refined and updated them (Fisher et al., 2005). Another incident occurred in  
1997 in Japan in which an episode of the Pokemon cartoon caused 685 children to visit 
hospitals with 560 cases shown to have had proven seizures triggered by a four-second 
sequence of alternating saturated red and blue light used in the program. Only 24% of those 
who had a seizure during the cartoon had previously experienced a seizure. Japan 
subsequently adopted formal guidelines on flashing and regular patterns based on the United 
Kingdom guidelines (Fisher et al., 2005). To facilitate broadcasting screening, the United 
Kingdom introduced an automatic screening device, “The Harding Test” (Cambridge 
Research Systems, Rochester, U.K.), which is an automated test for PIS-provocative image 
sequences in television content. The test screens for luminance flash activity, red flash 
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activity, extended flash warnings, number of luminance flashes, and number of red flashes 
(Harding and Takahashi, 2004). 
All these guidelines that evaluate the safety of artificial light-emitting sources in patients with 
PIS rely on comparison against stimulus parameters which are known to provoke seizures. 
However, such guidelines lack objective proof of safety. Moreover, no guidelines exist for 
light-emitting medical devices. One approach is to assess their safety using 
electroencephalography (EEG) while testing subjects under controlled conditions; such an 
approach has been used to assess pattern-induced seizures (Wilkins et al., 1979). For better 
understanding of how to use EEGs in such circumstances I will briefly review EEG changes 
during photic stimulation. 
1.4.2.5. Photosensitivity and electroencephalography  
 
During routine EEGs, intermittent photic stimulation (IPS) delivered via a stroboscopic light 
source is used as a provoking method to detect additional abnormalities. IPS effects on the 
human EEG were first studied by Adrian and Matthews in the 1930s (Schomer and Lopes da 
Silva, 2005). Walter et al were the first to report paroxysmal discharges elicited by IPS using 
strobe light (Walter et al., 1946).  The standard screening methods for assessing 
photosensitivity involve the presentation of IPS of varying frequencies (depending on the 
EEG laboratory) in trains of about 5 seconds duration, first with eyes closed and then with 
eyes open in a room with reduced illumination (Bickford et al., 1952). The three main EEG 
changes induced by IPS are: 1) photoparoxysmal response (PPR); 2) photomyoclonic 
response, and 3) photo-entrainment or photic drive response (PDR) (Schomer and Lopes da 
Silva 2005). 
1. Photoparoxysmal response (PPR). This occurs in 2.8% of patients referred for an 
EEG examination (Jeavons and Harding, 1975). It is characterized by spike-and-wave 
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or polyspike-and wave complexes which are bilaterally synchronous, symmetrical, 
and generalized. The response may outlast the stimulus by a few seconds. PPR can be 
elicited by a broad range of IPS frequencies (1 – 65 Hz), most commonly 15-18 Hz 
(15 Hz when eyes are closed and 20 Hz when they are open). Frequencies of 15 and 
20 Hz were reported to be the most commonly provoking frequencies in up to 96% of 
patients (Harding 1994), although this is subject to variability and may range from 
one flash per second to up to 84 flashes per second. 
2. Photo-myoclonic responses (PMR). These are characterized by forehead and muscle 
twitching in response to light flashes and disappear with eye opening (Fisher et al. 
2005). The signal on EEG is electromyographic in origin, arising in the orbicularis 
oculi and frontalis muscles in particular, though it can be associated with eyelid flutter 
(Fisher et al. 2005). The PMR is time-locked to the stimulus (Kasteleijn-Nolst Trenite 
et al., 2001). It is triggered by IPS frequencies ranging from 12 to 18 Hz. It occurs in 
in 0.3% of normal subjects, and 3% of patients with epilepsy (Schomer and Lopes da 
Silva 2005).  Other causes that may contribute to the occurrence of PMR include 
brain stem lesions, psychiatric disorders such as anxiety, alcohol withdrawal in 
chronic alcoholics, barbiturate withdrawal, and severe hypocalcaemia (Schomer and 
Lopes da Silva 2005). 
3. Photo-entrainment of alpha rhythm - Photic drive response- (PDR).   This is a 
physiologic response consisting of rhythmic RRG activity time-locked to the stimulus 
at a frequency identical to, or harmonically-related to, that of the stimulus. It is 
elicited over the posterior region of the head by IPS frequencies of about 5 to 30 Hz 
(Schomer and Lopes da Silva 2005). It is more likely to occur around a baseline 
background activity of 2-4 Hz (Blum and Rutkove, 2007). The PDR is considered 
abnormal in the following circumstances:  1) an amplitude asymmetry greater than 
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50% at all frequencies of stimulation usually associated with structural brain disease,  
2) an asymmetry in the development of the photic driving response associated with 
focal lesions of varying locations  (60%) or associated with generalized cortical 
atrophy and/or ventricular enlargement  (40%), or 3) the presence of unusual high-
amplitude single spikes evoked by individual light flashes seen in seen in patients 
with diffuse encehalopathies (Coull and Pedley, 1978). 
The source of the PDR is not fully understood. It was thought to be similar to visual evoked 
potentials due to the facts that the background rhythm is linked to the timing of the photic 
stimulator, the first response appearing shortly after the start of the stimulator (<100ms), and 
stopping when the stimulator stops (Blum and Rutkove, 2007). However, this does not 
explain why it happens in some people more than in others, nor why the response is not only 
identical to the IPS frequency but to its harmonics as well. 
Unlike the PPR, changes in the PDR in epilepsy patients are less explored. Our interest in the 
PDR in epilepsy and our attempt to understand it better by assessing the pupillary response 
derive from several facts: first, that the PDR has been linked to cortical excitability (Simon et 
al., 1982); second, anatomically the thalamus acts as a convergence point for three important 
pathways, the visual pathway (which relays to the lateral geniculate nucleus); the thalamo-
cortical pathway which plays a role in spike wave generation in epilepsy (involving the 
thalamic reticular nucleus)  (Huguenard, 1999); and third, the alpha rhythm generator- which 
is entrained during PDR- and  involves  a complex interaction between cortical and thalamic 
oscillators particularly the lateral geniculate nucleus (Hughes and Crunelli, 2005). For these 
reasons I speculated that the PDR would differ in epilepsy patients from the normal 
population.  
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1.5. Multifocal methods and pupillary response 
assessment in neurological disorders 
 
Visual evoked potentials (VEPs) have been used for many years in clinical neurology to 
demonstrate conduction delay in an optic nerve affected by inflammatory lesions, e.g. optic 
neuritis in multiple sclerosis (Polman et al., 2005). Changes in evoked potentials have also 
been seen in conditions leading to anatomical changes such as ischemic damage (Stoerig et 
al., 2002), neurotransmitter abnormalities such as Parkinson’s disease (Muthane et al., 1993), 
phenylketonuria (Schafer and McKean, 1975), and in paroxysmal disorders such as  migraine 
(Kennard et al., 1978) and epilepsy (Geller et al., 2005). However, these full-field pattern 
reversal stimuli involve presenting a single large stimulus to a relatively large proportion of 
the visual field, and measure a single aggregate VEP (the P100) using scalp electrodes placed 
over the occipital cortex. This technique has the potential to miss lesions which affect only a 
small portion of the visual field, since the VEP will pool responses from healthy and affected 
parts of the visual field. Due to these limitations the multifocal VEP (mfVEP) was developed. 
In mfVEPs many regions of the visual field can be tested independently and concurrently 
(Baseler et al., 1994), and this version of VEP has been reported to be better at detecting 
small lesions affecting the optic nerve (Davie et al., 1995). A more refined method has been 
developed by our laboratory in the Australian National University (James, 2009, Ruseckaite 
et al., 2005, James et al., 2005, James, 2003, Maddess et al., 2005) using temporally-sparse 
dichoptic stimuli. This method greatly enhances the signal-to-noise ratio permitting shorter 
test duration which is of more clinically-acceptable length. 
When considering multiple sclerosis (MS) as an example of a neurological disease and 
comparing different evoked potentials used to evaluate visual involvement, VEPs to full-field 
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pattern reversal stimuli can demonstrate increased latency in up to 90% of cases of clinically-
definite MS (Losseff et al., 1996). However, a more recent assessment of the sensitivity 
suggests that it is lower than previously reported, somewhere between  25% to 83% 
(Maddess et al., 2005). A conventional mfVEP stimuli yields a sensitivity of 92% but 
misdiagnoses more than 20% of the normal population. Sparse mfVEPs demonstrate 
comparative  sensitivity of 92% but at a false-positive rate of 0% (Ruseckaite et al., 2005).  
In the pursuit of further refinements multifocal pupillographic perimetry (mfPOP) was 
attempted (Figure 6) (Sutter, 1996, Tan et al., 2001, Wilhelm et al., 2000a). This technique 
allows objective perimetry based on the pupillary response pathway; thus it does not require 
the use of electrodes and involves little setup time. Like mfVEPs, mfPOP is capable of 
testing many parts of the visual fields of both eyes simultaneously. By testing both eyes with 
independent stimuli and recording from both pupils, the device can distinguish localized 
afferent and efferent defects (Bell et al., 2010, Carle et al., 2011b). Up to 176 pupillary 
responses can be obtained and analysed for both amplitude and delay (time-to-peak) (Figure 
7).  
MfPOP has been evolving over the last 10 years. Improvements have included slightly 
overlapping of bigger stimuli, and the introduction of sparse stimuli (Bell et al., 2010), 
luminance balanced stimuli, and clustered volleys stimuli (Sabeti et al., 2014). In the latter 
instead of appearing randomly across the field, the stimuli are presented in volleys within the 
hemifields but are randomized within each hemi-field. All these modifications have led to 
successive increases in signal-to-noise Ratio (SNR), permitting increasingly more stimuli per 
visual field, reducing test duration, and providing improved sensitivity and specificity in 
several diseases. 
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To date, mfPOP has been successfully evaluated in several conditions, including diabetic 
retinopathy (Bell et al., 2010, Sabeti et al., Sabeti et al., 2015), macular degeneration (Sabeti 
et al., 2012, Sabeti et al., 2014),  and glaucoma (Carle et al., 2011a, Carle et al., 2015). When 
used in MS patients, the predictive power of mfPOP to diagnose MS expressed as the 
percentage area under the curve (AUC) of the receiver operating characteristic (ROC) was 
found to be  69.8% for time-to-peak  in the relapsing remitting MS group and increased to 
85.5% in the progressive MS group; diagnostic power followed disability (Ali et al., 2014). 
Re-analysis of the published data using a method that examines asymmetries in response 
between the left and right eyes raises the corresponding %AUC values to 79.6 ± 3.03 and 
92.3 ± 5.23 (mean ± SE). The method employed in that MS study did not use the newer 
mfPOP methods with their increased signal quality. 
Accurate fast and objective measurements of visual fields were the goals set when designing 
the mfPOP device based on techniques originally developed for evoked potentials (James, 
2003, James et al., 2005, Ruseckaite et al., 2005). Although mfPOP has never been used to 
evaluate neither migraine nor epilepsy due to the fact that the two conditions were considered 
relative contraindications due to the fears that light emitted by the device during examination 
may exacerbate both conditions. Mfpop protocols do not fulfil light characteristics that are 
known to exacerbate epilepsy (described above). Overall, the mfPOP stimuli are unlikely to 
generate PSE on a number of counts. Firstly stimulation between the eyes is never co-
synchronous for any particular stimulus region. Each region stimulates much less than 10% 
of the cortex – this is perhaps the most important factor. The stimuli do not contain 5 to 8 
stripes. The stimuli do not have sharp edges and, in fact, their edges are roughly sine-wave 
gratings. The stimulus delivery rate at any one location is certainly less than 3 Hz. It is the 
case that our flicked stimuli alternate for several cycles at 15 Hz. However, their small 
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projected cortical excitation area, monocular presentation, blurred edges and lack of any 
stripes should render them quite ineffective at generating PSE. 
 The same can be said for migraine, yet to further reinforce its safety we designed two studies 
to indicate that commonly used mfPOP protocols are safe in the two conditions. Furthermore, 
protocols specifically designed and proven to stimulate melanospin containing RGCs in 
glaucoma subjects (Carle et al., 2015) were used in migraine patients. As mentioned above 
these ipRGS were found to play a role in exacerbation of headache by light (Noseda et al., 
2010).  Carle et al. (2015) found that several characteristics of the responses obtained to blue 
stimulation through mfPOP were indeed melanopsin-influenced. And although cone 
photoreceptors have participated in those responses to the blue protocol as sources of both 
excitatory and inhibitory input, pupil constriction amplitudes in the blue protocol were also 
substantially influenced by melanopsin.  
In addition to determining safety, our mfPOP studies will shed the light the pathophysiology 
of cortical excitability changes in migraine and epilepsy. Although the pupillary response is 
believed to be generated through a subcortical pathway it is important to note that the primary 
nucleus driving this response, the pretectal olivary nucleus (PON) receives significant 
cortical, ventral thalamic, midbrain and retinal inputs (Figure 8). Studies have identified 
well-defined ipsilateral projections from both striate and extra-striate visual areas to the PON 
such as area 17/V1 (Benevento et al., 1977), area 19 (Distler and Hoffmann, 1989, Lui et al., 
1995), the pupilloconstrictor region of area 20a (Distler and Hoffmann, 1989), V4 (Dineen 
and Hendrickson, 1983), the frontal and supplementary eye fields (Huerta et al., 1986, 
Leichnetz, 1982, Shook et al., 1990), dorsal prelunate, preoccipital cortex (Asanuma et al., 
1985) , inferior temporal cortex (Steele and Weller, 1993) and  lateral intraparietal region 
(Asanuma et al., 1985). Based on the number and variety of cortical regions projecting to 
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PON, a wide range of visual and oculomotor signals must have an impact on this nucleus and 
thus on the pupillary light reflex (Gamlin, 2006).  
The PON has reciprocal connections to the ventral thalamus, namely the ventral Lateral 
geniculate nucleus (LGNv), pre-geniculate nucleus (PGN) (Conley and Friederich-Ecsy, 
1993, Edwards et al., 1974, Graybiel, 1974, Ribak and Peters, 1975, Steele and Weller, 1993) 
and inter-geniculate leaflet (IGL) (Moore et al., 2000, Morin and Blanchard, 1998). This is an 
added reason why we feel that the pupillary response may serve as an important pathway to 
study migraine and epilepsy since the thalamus play a role in the pathogenesis of both 
disorders. In migraine the trigeminal ganglion signals are relayed to the spinal trigeminal 
nucleus, which projects to the lateral posterior nucleus and the  pulvinars – both parts of the 
thalamus - before relaying the input into the primary somatosensory cortex (Figure 5) and in 
epilepsy, the thalamo-cortical pathway plays an important role in spike wave generation in 
epilepsy (involving the thalamic reticular nucleus)  (Huguenard, 1999).  
Putting in mind that mfPOP is a subtype of evoked response generated by the pupillary 
pathway, with indirect cortical influence rather than being a direct cortically driven evoked 
response such as the VEP, we feel it will be ideal to study cortical excitability changes in 
migraine and epilepsy. 
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Figure 6. Measurement of pupillary responses. A) Schematic of the nuCoria Field 
Analyser®. Stimuli are presented independently on two LCD monitors (a). These 
images are reflected by two dichroic mirrors (b) allowing infrared light to pass while 
reflecting shorter wavelengths. Viewing distance is increased to optical infinity by 
plano-convex lenses (c). Each eye views only one monitor, the images being fused by 
the subject into a cyclopean view. Infrared illumination of the eyes is provided by 
infrared light-emitting diodes (d) facilitating the monitoring of each pupil by separate 
infrared video cameras (e). Pupil diameters are then extracted in real-time and recorded 
by a computer (f). B) The 44 stimulus regions per eye were arranged in a dartboard-like 
polar layout extending to 30° from fixation. C) Showing the independent stimuli 
(dichoptic) from a series of video frames of the test sequence. Stimuli were pseudo-
randomly presented to each hemifield of each eye in a consecutive series. The faint 
background starburst pattern assists the subjects to fuse the images. 
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Figure 7. Example mfPOP response waveforms from an individual subject (Above). 
The mean pupil responses to stimuli present to each of the 44 test regions were obtained 
from both eyes concurrently from 6 minutes of stimulation. Downward deflection 
indicates contraction. The red and green traces of the upper plot are the responses of the 
left and right pupils. (Below) Pupil responses are analysed according to amplitude and 
delay (time-to-peak). 
 
46 
 
 
Figure 8. Non-retinal afferent connections of the pretectal olivary nucleus. 
Adopted from (Gamlin, 2006). 
FEF=frontal eye fields; SEF= supplementary eye fields; LGNv= ventral lateral 
geniculate nucleus; PGN= pregeniculate nucleus; IGL= intergeniculate leaflet; SC= 
superior colliculus; LTN= lateral terminal nucleus; DP= dorsal prelunate; POC= 
preoccipital cortex; IT= inferior temporal cortex; LIP= lateral intraparietal region.  
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Aims and summary  
 
The purpose of this thesis was to evaluate the phenomena of photosensitivity and 
cortical hyper-excitability in two distinct but overlapping disorders, namely epilepsy 
and migraine using the multifocal objective pupillographic perimetry device, which 
allows assessment of the cortical and subcortical parts of the visual pathway 
responsible for the pupillary response. Based on the above knowledge, our hypotheses 
are as follows: 
1- The mfPOP protocols that involve light are safe when used to examine epilepsy and 
migraine subjects. 
2- Cortical excitability changes in migraine and epilepsy disorders extend to involve 
subcortical pathways namely the pupillary response. 
3- Stimulating melanospin containing retinal ganglion cells will lead to exacerbation 
of migraine headaches. 
The objectives of the research in this thesis were done to first evaluate the multifocal 
objective pupillographic perimetry responses in normal, migraineurs, and patients with 
epilepsy, and to assess if there are subtypes of epilepsy and migraine which can be 
identified by mfPOP. 
Second, to provide evidence that mfPOP protocols, that involve light stimulation, are safe 
and tolerable when used in migraine and epilepsy patients. This is of great importance 
before using this device on a wide scale in these groups of subjects. To further reinforce 
this point protocols designed specifically to stimulate melanopsin-containing retinal 
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ganglion cells in migraine subjects were used to examine whether stimulating this 
pathway will lead to exacerbation of migraine headaches. 
The third Objective was to evaluate the factors that might influence these responses such 
as attack timing and medication use. Finally EEGs recorded from epilepsy subjects 
looking at changes in the alpha rhythm entrainment in response to photic stimulation were 
analysed serving as an added indicator of cortical excitability. 
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Chapter 2.   
 
 
Effects of stimulating 
melanopsin-containing retinal 
ganglion cells in migraine patients 
using multifocal objective 
pupillometry:  
a randomized controlled cross over 
study 
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Abstract 
 
Hypothesis: Stimulating melanospin containing retinal ganglion cells may lead to 
exacerbation of migraine headaches. Aim: To establish the effects of stimulating 
intrinsically-photosensitive retinal ganglion cells (ipRGCs) on migraine severity and 
pupillary response characteristics, and to determine if there are differences in the 
pupillary response characteristics between migraineurs and controls. Design/Methods: 
A randomized, open labelled, crossover study tested migraineurs and normal controls 
using multifocal pupillographic objective perimetry (mfPOP) with 44 test-regions/eye. 
A blue protocol (BP) stimulated ipRGCs, and a yellow protocol (YP) stimulated cone 
photoreceptors. Migraine diaries assessed migraine severity. Responses were analyzed 
according to response time-to-peak and standardized amplitude (AmpStd). Results: 36 
migraineurs (42.0 ± 16.5 years, 23 females) and 24 normal controls (39.2 ± 14.8 years, 
14 females) were tested. Only one patient had difficulty completing the tests and 
reported the occurrence of an aura. The percentage of subjects developing a migraine 
attack did not differ after either protocol, either during the 1st day (odds ratio 1.0; 95% 
confidence interval 0.2-4.4, p = 0.48) or during the first three days after testing (odds 
ratio 0.8; 95% confidence interval 0.3-2.1, p = 0.68). Migraine days/week did not 
increase following testing with either protocol in comparison to the baseline week (1.4 
± 1.6 pre-testing (mean ± SD), 1.3 ± 1.4 post-BP, and 1.3 ± 1.2 post-YP; p = 0.96), 
neither did other measures of severity. Pupillary response characteristics including 
AmpStd and time-to-peak did not differ between migraineurs and controls. Looking at 
effects of headache characteristics on the pupillary response in migraineurs we found 
that a migraine attack occurring prior to testing had a significant independent effect in 
lowering AmpStd while a history of triptan use increased AmpStd. Conclusions: 
Stimulating ipRGCs did not affect migraine occurrence or severity. Pupillary response 
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characteristics were influenced by the occurrence of a recent migraine attack and a 
history of triptan use; these changes might be the result of the cortical spreading 
depression which is associated with migraine attacks. 
 
2.1.     Introduction 
 
Migraine headaches are associated with cortical spreading depression (CSD) which 
consists of a wave of profound depression in neural activity preceded by neuronal 
activation. CSD is believed to underlie migraine aura and to be a trigger for the 
headache pain in migraine (Grafstein, 1956).  Light is a well-recognized trigger of 
migraine attacks (Martin, 2010). How the pathways involved in light perception might 
be affected in migraine subjects is still not fully understood. Noseda et al (2010) have 
recently described a retino-thalamic pathway which arises from a subset of retinal 
ganglion cells (RGCs) called intrinsically-photosensitive RGCs (ipRGCs). This 
pathway may be responsible for headache exacerbation. ipRGCs contain the 
photosensitive pigment, melanopsin, and relay their responses to cells in the posterior 
thalamus, among other targets. These same cells in the thalamus also receive input from 
the trigemino-vascular pathway which is believed to carry the pain signal arising from 
the dura mater during migraine attacks (Noseda et al., 2010). The output of these cells 
is fed to the somatosensory cortex. Melanopsin, and thus direct ipRGC activation, is 
most sensitive to blue light, its sensitivity peaking at 479 nm (Kawasaki and Kardon, 
2007). Also, intense stimuli of long duration are required for optimal activation of the 
ipRGCs. Whether such stimuli have the ability to stimulate this retino-thalamic 
pathway, and so be capable of exacerbating a migraine attack, remains to be explored. 
A more recent study showed that melanopsin is expressed in both human and mouse 
trigeminal ganglion neurons- classic pain sensory neurons- and these isolated neurons 
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respond to blue light stimuli with a delayed onset and sustained firing, similar to the 
melanopsin-dependent intrinsic photosensitivity observed in ipRGCs. They have also 
been shown to be responsible for light detection in the Central nervous system via a 
non-optic nerve pathway (Matynia et al., 2016). A previous study conducted by Main et 
al. (2000) observed that migraine patients found both short (blue) and long (red) 
wavelengths of light significantly more uncomfortable between attacks in comparison 
to normal controls and subjects with tension-type headache. However, these results 
were only based on subjective measures.  
Multifocal Pupillographic Objective Perimetry (mfPOP) is a diagnostic technique that 
objectively assesses visual function using the pupillary response. The device tests 44 
locations in the visual fields of both eyes concurrently using pupil responses. By testing 
both eyes with independent stimuli and recording the response of both pupils the device 
can distinguish localized afferent and efferent defects (Bell et al., 2010, Carle et al., 
2011b). Alterations in pupillary response have been described in migraine patients 
clinically: prolonged mydriasis has been reported during migraine attacks, sometimes 
persisting for up to three months after an attack, suggesting a dysfunction of the 
ipsilateral ganglionic system(Cambron et al., 2014, Barriga et al., 2011). However, 
conventional pupillometry has so far failed to confirm these findings (Cambron et al., 
2014). In addition, visual field defects have been documented in relation to migraine 
attacks (McKendrick and Badcock, 2004b, McKendrick and Badcock, 2004a). To date, 
the diagnostic power of mfPOP in detecting visual field defects has been successfully 
evaluated in several conditions including multiple sclerosis (Ali et al., 2014), diabetic 
retinopathy (Bell et al., 2010, Sabeti et al., Sabeti et al., 2015), macular degeneration 
(Sabeti et al., 2012, Sabeti et al., 2014),  and glaucoma (Carle et al., 2011a, Carle et al., 
2015). Consequently, in view of the confusion in the literature addressing changes in 
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the pupillary response in migraine this study was designed to use mfPOP to 
characterize the pupillary responses and document visual field defects in patients with 
migraine. The stimuli used in previous studies with mfPOP were transiently-presented 
yellow stimuli designed to drive red and green cones. We have used long-duration blue 
mfPOP stimuli targeting ipRGCs in a study of 19 glaucoma patients and 24 control 
subjects (Carle et al., 2010, Carle et al., 2015) without obvious side-effects, though 
migraineurs were not specifically examined.   
This study aimed first to determine whether testing migraine patients with mfPOP 
would exacerbate their symptoms if a long-duration blue stimulus designed to stimulate 
the ipRGCs was used. This stimulus was compared to the standard mfPOP transient 
yellow stimulus designed to drive cone photoreceptor input to ipRGCs rather than 
stimulate their intrinsic response. A second aim was to estimate the power of mfPOP to 
quantify effects of migraine. The final aim was to determine the pupillary response 
characteristics and pattern of visual field defects of migraine subjects, along with any 
factors that might influence them. 
2.2.  Methods  
2.2.1. Study Design and Subjects 
 
A randomized, controlled, open labeled crossover single-site study was undertaken over 
a one year period between 2012 and 2013 (Figure 1).  
Subjects with migraine were recruited from staff and students at The Australian 
National University and via local neurologists at The Canberra Hospital in Canberra, 
Australia. Recruitment occurred via poster advertisement, letters, and email circulation. 
Informed, written consent was obtained from all subjects. The study conformed to the 
Declaration of Helsinki guidelines and was approved by both the Human Research 
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Ethics Committee of the Australian National University (2012/278) and the ACT 
Health Human Research Ethics Committee (ETH.3.12.064). 
Inclusion criteria comprised: 1) age above 18 years, 2) a clear diagnosis of migraine 
with or without aura according to International Headache Society criteria (2013)  3) 
corrected visual acuity in both eyes better than 6/12. Exclusion criteria included: 1) a 
history of other visual or neurological disturbance that might affect visual assessment, 
2) a history of epilepsy, 3) colour blindness, 4) pregnancy, 5) medication that could 
affect pupillary responses, 6) migraine headache occurring within the 24 hours prior to 
testing.  The control group consisted of age- and sex-matched normal healthy controls.  
Sample size calculation suggested that a total of 22 migraine subjects and 22 controls 
would be needed.  In order to detect an effect size of 40% increase in migraine 
headache or aura occurrence after testing with the mfPOP device. The power was set at 
80% using a two-sided t-test at the level of p = 0.05. This calculation was done using 
the sample size formula for proportions (Lawrence M. Friedman, 2010). 
A screening session to establish eligibility was performed for each participant during 
which a complete history to establish the diagnosis by the investigator along with 
background information regarding age at migraine onset, typical triggers, pattern, 
frequency and duration of migraine, presence of photophobia, other headaches, time 
since the most recent headache attack, and medication use (therapeutic or preventative) 
was obtained. Medications were divided according to class into triptans, opioids or 
over-the-counter (OTC) medications (NSAIDs, aspirin and paracetamol). A complete 
neurological examination to exclude other neurological disorders was conducted 
including confrontation visual field testing. 
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Subjects and controls were asked to complete a baseline headache diary for one week. 
This was felt to be an appropriate duration granted the short mfPOP testing time. 
Participants were then randomized using Research Randomizer software (Urbaniak and 
Plous, 2013) to undergo one of the two mfPOP testing protocols (Figure 1). The 
randomized crossover design minimized the influence of confounding covariates 
because each patient acted as their own control. After each test a second diary was 
completed for a week followed by a washout period of a week. Subjects then underwent 
the other mfPOP protocol (see below) after which they completed a third headache 
diary. For ethical reasons, the use of subjects’ usual pain-relieving medications was 
permitted. This enabled evaluation of trends in medication use before and after testing 
and was felt to be likely to increase adherence to the study. All participants were 
advised not to smoke, drink caffeinated beverages, or consume alcohol during the six 
hours prior to testing.  
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2.2.2. Migraine diaries 
  
A validated migraine headache diary devised by The Diagnostic Headache Diary Study 
Group (Jensen et al., 2011) was used on the three occasions described above  (Figure 
2). 
Parameters recorded included whether the subject experienced a migraine headache 
(yes/no), severity on a scale of 1-3 (1= not bad, 2= quite bad, 3= very bad), duration 
(estimated from the time the first symptoms were noticed until the time the headache 
finally subsided), characteristics (throbbing or compressing /unilateral or bilateral), 
associated factors (presence of aura, photophobia, phonophobia, nausea vomiting), 
precipitating and relieving factors, as well as medication consumption (including type, 
dosage and frequency). 
2.2.3.  MfPOP assessment 
 
All subjects underwent mfPOP assessment using the nuCoria Field Analyser® 
prototype (nuCoria Pty Ltd, Canberra, Australia) (Figure 3). The components of the 
FDA-cleared device are described in (Figure 3A). Corrective lenses compensate for 
any refractive error. Stimuli were presented by a pair of liquid crystal displays (LCD) 
and reflected by cold dichroic mirrors to the two eyes simultaneously, these types of 
mirrors were used to allow infra-red light through to permit illumination and videoing 
of the irises. The cameras operated a 60 frames/s and a resolution of 512x768 pixels. 
The forty-four pseudo-randomly presented individual stimuli/eye were arranged in a 
dart-board like pattern extending to ±30°eccentricity of visual field (Figure 3B, C). To 
reduce the effects of possible light scatter from adjacent regions a background 
illumination of 10 cd/m2 was used to adapt rod photoreceptor responses (note that 
commercial perimeters provide this light level to light adapt the rods to reduce 
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responses to weak scattered light). To minimise any accommodative response the 
display included a small central (binocular) red cross to assist the subject to fixate at 
optical infinity, in addition, computer monitoring of fixation was used. Stimuli were 
presented dichoptically to each eye, and both direct and consensual responses were 
obtained from each tested visual field region.  
Relative (rather than absolute) pupil diameter was recorded by video cameras using 
infrared illumination with settings unified for both protocols. Only the lower 75% 
portion of the pupil was recorded to avoid potential problems generated by ptosis. 
Stimuli were presented in 9 segments. If more than 15% of a segment was lost, that 
particular recording segment was repeated.  
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Figure 3. Measurement of pupillary responses. A) Schematic of the nuCoria Field 
Analyser®. Stimuli are presented independently on two LCD monitors (a). These 
images are reflected by two dichroic mirrors (b) allowing infrared light to pass while 
reflecting shorter wavelengths. Viewing distance is increased to optical infinity by 
plano-convex lenses (c). Each eye views only one monitor, the images being fused by 
the subject into a cyclopean view. Infrared illumination of the eyes is provided by 
infrared light-emitting diodes (d) facilitating the monitoring of each pupil by separate 
infrared video cameras (e). Pupil diameters are then extracted in real-time and recorded 
by a computer, this also allowed the investigator to have a view of the pupil images 
during real-time recording (f). B) The 44 stimulus regions per eye were arranged in a 
dartboard-like polar layout extending to 30° from fixation. C) Showing the independent 
stimuli (dichoptic) from a series of video frames of the test sequence. Stimuli were 
pseudo-randomly presented to each hemifield of each eye in a consecutive series. The 
faint background starburst pattern assists the subjects to fuse the images.  
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2.2.4.  Stimulus characteristics 
 
There were two stimulus methods (protocols) used and the characteristics of each 
protocol are summarized in (Table 1).  
The “yellow” protocol (YP) – the standard mfPOP testing protocol – was designed to 
stimulate cone photoreceptors. It involved stimuli with a maximum luminance of 150 
cd/m2 and individual stimulus duration of 33 msec. Test duration was 6 minutes divided 
into 9 segments, each of 40 s duration, with additional rest periods of several seconds 
between segments.    
The “blue” protocol (BP) was designed to stimulate the intrinsic response of ipRGCs 
(Carle et al., 2015), and involved presentation of blue stimuli corresponding to 479 nm 
with a maximum luminance of 75 cd/m2 (Figure 4). This wavelength was chosen based 
on the response of a primate melanopsin-expressing ganglion cell to a 470 nm light 
pulse where those cells continued to fire action potentials for 30 seconds after the end 
of the light stimulus (Lucas et al., 2001, Kawasaki and Kardon, 2007).  Stimulus 
chromaticities are given in Table 1, and the relative cone excitations are given in 
(Figure 4). Evidence that the BP protocol does simulate the ipRGCs has been 
published elsewhere (Carle et al., 2015).  
For both protocols the array of 44 stimuli extended to ±30° eccentricity to cover the 
area of retina with the highest ipRGC density (greatest toward the fovea with peak 
density of 20-25 cells/mm2) (Dacey et al., 2005).  The probability of absorbing a photon 
by an ipRGC is >1 million times lower than in rods or cones for a given area of photic 
stimulation (Do et al., 2009). Hence, the BP stimulus duration was increased from the 
standard 33msec to 1 sec to ensure optimal melanopsin-driven sustained pupil 
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responses (Park et al., 2011). Also ipRGCs integrate the melanopsin signal over a 
second or more (Dacey et al. 2005). As with YP the test duration was six minutes. That 
test duration is the standard mfPOP testing duration used in many studies (excluding 
breaks) and was felt to be sufficient based on previous work by Cao who found that a 
mean time of 6.88 minutes was needed to trigger a migraine in 61.5% of subjects 
shown a provoking visual stimulus (Cao et al., 1999).   
 
 
 
 
Table 1. Stimulus characteristics 
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Figure 4. Stimulus characteristics. (A) C.I.E. coordinates for the colors used in the 
study. The crosses in grey represent the background, and the black crosses are the 
stimulus. (B) Proportional cone activations for the yellow and blue protocols. 
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2.2.5.  Data Analysis  
 
Analysis was conducted using MATLAB software (MathWorks, Natick, MA). 
Response waveforms – for both direct and consensual responses – from each region of 
the visual field were obtained and fitted to a log-normal function as follows: 
v(t)= A exp ( -[ In(t/tp) ]2   /   2σ2  )   
Where v(t) is the response waveform, A is the peak amplitude, t is the time at which 
each estimation is made, tp is the time to peak, and σ is the width of the response (Bell 
et al., 2010, Carle et al., 2011a, Carle et al., 2013).  
This allowed the characterization of the responses according to standardized amplitude 
(AmpStd) and time-to-peak (Figure 5). AmpStd assessed any change in pupil size 
corrected to the mean diameter of the population rather than using absolute pupil size 
and was expressed in decibels (dB). It was derived from contraction amplitude as 
follows: 
AmpStd = contraction amplitude (µm) x 3500/c  
Where c is the mean pupil diameter based on the value of a line fitted to the entire 240 
seconds of pupil diameter data recorded during each test, and 3500 m is the nominal 
population mean. 
AmpStd was used to overcome inter-subject variation in mean pupil diameter and also 
improved tolerance to non-circular pupils.  The higher the AmpStd, the larger the 
magnitude of pupillary constriction. 
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Figure 5. Example mfPOP response waveforms from an individual subject. The 
mean pupil responses to stimuli present to each of the 44 test regions were obtained 
from both eyes concurrently from 6 minutes of stimulation. Downward deflection 
indicates contraction. The black and grey traces are the mean responses of the left and 
right pupils. 
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Student’s t-tests and Fisher’s exact tests were used to compare baseline characteristics. 
Odds ratios, McNemar’s and Cochran’s q tests, and one-way between-subjects 
ANOVAs were conducted to compare the number of subjects developing migraine after 
each protocol – the primary outcome – and the effect of mfPOP testing on other 
migraine parameters. Multivariate linear models were used to assess the independent 
effects of migraine parameters on the pupillary response. 
The percentage area under the curve (AUC) of the receiver operating characteristic 
(ROC) plot was used as a measure of the power of mfPOP to predict migraine diagnosis 
i.e. it quantified the overall ability of the mfPOP to discriminate between individuals 
with and without migraine. ROC plots were constructed for both AmpStd and time-to-
peak in both protocols, using either the single worst region in each field (i.e. the one 
most deviating from normal) or the mean of the five worst regions, looking at either 
single eyes or at the asymmetry between anatomically equivalent regions of the two 
eyes (Bell et al., 2010). 
 
2.3.   Results 
 
Forty migraine patients (Table 2) were screened and 39 enrolled (Figure 1). Thirty-
eight subjects completed testing with both mfPOP protocols. Two subjects were 
excluded because they developed a migraine within the 24 hours prior to testing, one 
patient withdrew after the first test, and four subjects did not return completed diaries.  
In all, thirty-two sets of completed migraine diaries were returned and analyzed. In 
addition, 24 age- and gender-matched controls were studied. 
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Table 2. Subject characteristics  
 
Subjects  
(n=36)  
Controls  
(n=24)  
Age (mean ± SD)  42.0 ± 16.5  39.2 ± 15.2  
Male: Female  1 : 1.8  1: 1.5  
Migraine type  
•   With aura  
•   Without aura  
 
26 (72%) 
15 (42%) 
-  
Mean age of onset (±SD)  17.8 ± 9.11  -  
Mean disease duration (±SD)  24.3 ± 16.7  -  
Treatment  
• Preventative  
• During attacks                        
                      Over the counter  
                      Triptans  
                      Opioids  
                      Ergot  
  
8 (22%) 
   
25 (69%) 
14 (39%) 
13 (36%) 
 2 (6%) 
-  
Mean attacks per month (±SD)  2.62 ± 5.17  -  
Mean headache duration (hours) (±SD)  11.75 ± 16.5  -  
Trigger  
• Light  
• Other  
 
15 (41%) 
32 (88%) 
-  
Photosensitivity  34 (94%) -  
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2.3.1. Effects of mfPOP stimulation on migraine 
headache severity parameters 
 
Only one patient had difficulty completing the BP, reporting the occurrence of an aura 
at the end of the test. Otherwise, all patients reported no discomfort during testing apart 
from mild tearing due to lack of blinking. The effects of testing on other migraine 
parameters are summarized in (Table 3) which shows the same number of patients – 
four subjects (12.5%) – developing a migraine attack in the first day after testing with 
either BP or YP. The difference was not significant (odds ratio 1.0; 95% confidence 
interval 0.2-4.4, p = 0.48). The results remained non-significant testing both protocols 
over the first 72 hours, with 11 subjects (34.4%) developing migraine post-BP and 13 
subjects (41%) post-YP (odds ratio 0.8; 95% confidence interval 0.3-2.1, p = 0.68). 
This period of 72 hours was examined based on evidence that it may take up to 48 
hours from a trigger for a migraine to occur (Zagami and Bahra, 2006). In comparison 
to pre-testing, migraine days / week were not significantly increased: 1.4 ± 1.6 pre-
testing (mean ± SD), 1.3 ± 1.4 post-BP, and 1.3 ± 1.2 post-YP (both p = 0.96). Other 
migraine parameters including attack severity, attack duration, and percentage of 
patients taking medication before and after each test were also not significantly 
different. 
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Table 3. Effects of mfPOP stimulation on migraine headache severity 
parameters 
 
 
 
 
 
 
 
 
aMcNemar’s test 
b One way ANOVA 
c Cochran’s Q test 
                           
 
Parameter Pre-testing Post-BP Post-YP P value 
 
Patients experiencing 
migraine in the  1st day 
post testing (number, 
% ) 
- 4 (12.5%) 4 (12.5%) 0.48a 
Patients experiencing 
migraine within 3 days 
post testing (no, %) 
- 
 
11(34.4%) 
 
13(41%) 
 
0.68a 
 Migraine 
days/week(mean ± SD) 
 
1.4 ± 1.6 
 
1.3 ± 1.4 
 
1.3 ± 1.2 
 
0.96b 
% of patients 
experiencing quite bad  
to very bad migraine  
34% 25% 43% 0.10c 
Mean attack duration 
(hours)  
1.41 1.09 1.07 0.71b 
% of patients taking 
medication   
50% 50% 
 
 
53% 
 
0.93c 
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2.3.2. Changes in the mfPOP pupillary response 
characteristics  
 
Results for mean AmpStd and time-to-peak are summarized in (Table 4) No significant 
differences were found between patients and controls during either BP or YP. However, 
there was a shorter time-to-peak during YP (493.5 ± 25.7 ms in controls and 494.9 ± 
22.3 ms in migraineurs) compared to BP (594.9 ± 55.2 ms in controls and 604.3 ± 48.8 
in migraineurs), probably related to the large difference in the duration of the stimuli 
and the very slow response time of ipRGCs. 
2.3.3. Effects of headache characteristics on the 
pupillary response in migraineurs 
 
The closer a migraine attack occurred prior to the time of testing, the more negative the 
effect upon AmpStd, i.e. less pupillary constriction in both protocols (Table 5). The 
greatest reduction was seen if the attack occurred within one week prior to testing, 
followed by two weeks and, lastly, two months prior to testing. There was no 
“predictive” effect of mfPOP associated with a migraine that was about to occur in the 
week following testing, i.e. no changes in the pupillary response were seen before a 
migraine attack was about to happen (results not shown). Looking at the effect of 
medications, the use of triptans was associated with a significant increase in AmpStd in 
both YP and BP (0.45 ± 0 .09 dB, and 0.48 ± 0.07 dB, respectively, p < 0.001). This 
was not seen for other therapeutic medications (OTC medications, opioids, etc.) or 
preventative therapies. Although the presence of other types of headaches (mainly 
tension headaches) was associated with a significant change in amplitude, the number 
of patients was too small to allow further comment.  
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Table 4. mfPOP results for the Blue and Yellow protocols. 
 
 
 
 
 
 
 
  
Control 
(mean ± SE) 
Migraine 
(mean ± SE) 
Blue protocol  
AmpStd (dB) 
 
9.48 ± 10.4 9.05 ± 11.5 
Time-to-peak 
(ms) 
 
594.9 ± 55.2 604.3 ± 48.8 
Yellow 
protocol  AmpStd (dB) 
 
11.4 ± 5.23 10.8 ± 6.25 
Time-to-peak 
(ms) 
 
493.5 ± 25.7 494.9 ± 22.3 
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Table 5. Independent Effects of headache Parameters on AmpStd in 
migraine subjects. 
 
 
 
 
* Male patients aged 40 without migraine in the last 60 days and no triptan use.  
AmpStd values used were the mean for each subject of the 22 weakest contracting 
regions relative to normal in decibels. Other factors included in the multivariate linear 
models include age and consensual pupillary responses.  
 
Blue protocol Yellow protocol 
dB ± SE  P value dB ± SE P value 
(Reference) * -0.96 ± 0.11 - -0.70 ± 0.09 - 
Migraine within last  60 
days (n=26) 
-0.45 ± 0.16 0.004 -0.08 ± 0.11 0.501 
Migraine within last  2 
weeks (n=24) -0.64 ± 0.14 <0.001 -0.65 ± 0.11 <0.001 
Migraine within last  week 
(n=19) -0.80 ± 0.10 <0.001 -0.57 ± 0.08 <0.001 
Female gender (n=22) 0.07 ± 0.10 0.448 0.42 ± 0.07 <0.001 
Triptan (n=13) 0.45 ± 0.09 <0.001 0.48 ± 0.07 <0.001 
Other headaches (n=2) 2.40 ± 0.25 <0.001 -1.17 ± 0.14 <0.001 
80 
 
2.3.4. Visual field defects detected by the mfPOP 
 
(Figure 6) Shows examples of visual field abnormalities seen in migraine subjects 
demonstrating deviations in AmpStd from normal (images taken in response to the YP). 
In general, these defects were seen with both the YP and BP. They were mainly 
concentrically located, affecting the peripheral visual fields and were asymmetric 
between the two eyes: in some cases they were monocular but a few were homonymous 
in nature. These defects were seen less in subjects with migraine without aura, and 
when measurement were further in time from the last migraine attack. Grey scale plots 
(Figure 7) representing the mean deviations in AmpStd taken from all migraine 
subjects in response to both the YP and BP from normal controls, again abnormalities 
were on average more pronounced in the periphery of the visual fields. Although 
averages around rings are sometimes used in multi-focal methods there appears to be no 
obvious ring-structure. 
2.3.5. The power of mfPOP to predict the diagnosis of 
migraine 
 
(Table 6) shows that the ROC %AUC ranged between 65% and 77% for AmpStd, with 
BP performing marginally better than YP. Better performance was achieved using 
smaller subsets of regions (the single most deviating test region in visual field or the 
mean of the worst 5 regions), rather than the mean pupil response across regions 
indicating significant localised scotomas. When asymmetry between the eyes was 
analysed, the %AUC increased to 88% for BP and 81% for YP. The asymmetry values 
is calculated as absolute value of the difference between visual field locations that are 
analytical equivalent, i.e. temporal and temporal field locations, nasal and nasal 
locations. Thus there are 44 asymmetry measures per patient (Bell et al., 2010, Sabeti et 
al. 2014, Sabeti et al., 2015). 
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Figure 6. Examples of visual field defects from the YP detected by the mfPOP device 
showing deviation in AmpStd from normal in four migraine subjects, results from each 
subject being in a 2 x 2 block of plots labelled A to D. The darker the region the more it 
deviates from normal. The top row of each set of four represents responses recorded by 
the left pupil, and the bottom row the right pupil. Direct responses are thus labelled A 
and D, and consensual responses B and C.  Afferent defects will be in agreement for an 
eye and across pupils (across a vertical pair), effect defects would be consistent for a 
given pupil (across a horizontal pair) and not in agreement across eyes. Here the defects 
mainly appear to be afferent.  
 
 
82 
 
 
 
 
 
 
 
 
Figure 7. Gray scale plots showing mean deviations of AmpStd in migraine 
patients from normal controls in response to both the YP (right column) and BP 
(left column) (top row) represents normal controls; (bottom row) represents migraine 
effects (difference from normal base on linear models). Patients show reductions in 
sensitivity (darker tones) that are perhaps greatest in the periphery. 
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Table 6. %AUCs for blue and yellow protocols. 
 
 
 
 
 
 
 
 
 
 
Blue protocol (%)  Yellow protocol (%) 
AmpStd each eye: 
.  Worst point / 44 
.  Mean of worst 5 pts  
 
76.7 ± 4.40 
65.2 ± 5.06 
 
72.0 ± 4.65 
68.4 ± 4.88 
Asymmetry between eyes: 
.  Worst point / 44 
.  Mean of worst 5 pts  
 
88.3 ± 4.06 
73.8 ± 4.52 
 
80.6 ± 4.24 
75.0 ± 4.88 
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2.4. Discussion 
 
The results show that the mfPOP device is relatively safe and well tolerated when used 
in migraine patients. There was no increase in the incidence or severity of migraine 
headaches, even when using the blue stimulus which was specifically designed to 
stimulate the melanopsin-containing ipRGCs. We have shown similar results in 
epilepsy patients (Chapter 3), and the lab has recorded over 14,000 mfPOP tests on 
over 3800 subjects without a complaint of a migraine or seizure. The mean pupillary 
response characteristics determined by mfPOP in migraine patients did not differ from 
those of controls. However, there was a significant reduction in pupillary constriction 
associated with a migraine attack occurring prior to testing. Being a user of triptans was 
associated with the opposite effect i.e. pupillary constriction was increased. mfPOP was 
moderately able to distinguish patients from controls with BP performing better than 
YP detecting visual fields defects consistent with the scintillating  scotomas reported by 
migraine patients.  
Based on the work of Noseda et al. that pointed to a role of the melanopsin containing 
ipRGCs in the exacerbation of migraine headaches (Noseda et al., 2010) new 
modalities to treat migraine have emerged such as pharmacological manipulation of 
melanopsin (Jones et al., 2013) or blocking of blue wavelengths using tinted lenses 
(Good et al., 1991). Therefore, it is important to understand the effects of ipRGC 
stimulation on migraine pathophysiology. This study is the first to use a stimulus 
specifically designed to target the melanopsin-containing ipRGCs in order to look for 
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an effect on migraine occurrence. In addition to being responsible for the Post-
illumination Pupil Response (PIPR), results by Gamlin et al also suggested that 
melanopsin has a substantial influence on early pupillary response constriction in 
macaques. This was proved during retinal illumination at 493 nm and pharmacological 
blockade of rod and cone inputs, and finding the pupillary response to be present 
despite being delayed by approximately 1 s and  more sluggish than normal. This 
consistent with the idea that the ipRGCs controls the acute phase of the pupillary 
response (Gamlin et al., 2007). 
Furthermore Carle et al found that the stimulus response functions - namely the pupil 
constriction amplitudes - for the blue stimuli obtained through mfPOP matches that of 
the melanopsin containing RGCs (Carle et al., 2015). The stimuli were specifically 
designed to eliminate light characteristics that could potentially cause discomfort in 
migraine subjects; stimuli were small and brief (33 to 1000 ms) and were delivered 
randomly to any location in the visual field (i.e. stimulation of the two eyes was never 
co-synchronous in any part of the visual field). Thus, each stimulus activated much less 
than 10% of the visual cortex at any given time (Hay et al., 1994). The stimuli did not 
contain stripes or checks (Marcus and Soso, 1989), had smooth edges like sine-wave 
gratings, and contained no high spatial frequencies above 2.0 cyc/deg. Thus, color and 
duration were the main characteristic that could have contributed to any effect that the 
stimulus might have had on triggering a migraine attack.  
When looking at the mean pupillary responses obtained by mfPOP, the results are in 
agreement with Cambron et al. (Cambron et al., 2014) who studied autonomic function 
in migraine patients during both ictal and interictal phases using pupillometry and 
found no significant difference between migraine sufferers and controls in either phase 
in terms of latency, amplitude of constriction, minimum diameter, constriction and re-
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dilatation speeds. However it is important to point out that, when looking at changes in 
responses to some parts of the visual field as opposed to the overall mean across the 
field, it was possible to detect differences when testing was conducted shortly after an 
attack or after triptan use. These changes were unlikely to be due to a generalized 
autonomic dysfunction accompanying migraine attacks as such changes would generate 
equal defects in all regions. One speculation is that the abnormalities represent small 
visual field defects (or migraine scotomas) resulting from cortical spreading depression 
(CSD) (Grafstein, 1956). Looking further at these defects they were found to be 
asymmetric between the two eyes, concentrically arranged, and localized to the 
peripheral fields (Figs. 6 and 7). In some subjects they were monocular and a very 
small number had homonymous defects. With increasing time after an attack these 
defects were observed to be smaller in magnitude. The results are consistent with 
previous work by the MacKendrick group who found similar defects using static and 
temporal modulation perimetry (McKendrick et al., 2000). None of the visual defects 
they detected were consistent with a cortical locus (i.e. bilateral homonymous deficits), 
which made them speculate that they were due to a pre-cortical visual dysfunction. 
They suggested that defects in the magnocellular visual pathways which also contribute 
to the pupillary response (Alpern and Campbell, 1962{Tsujimura, 2003 #475) may be 
responsible for theses visual disturbances based on selective loss for targets temporally 
modulated by either motion or flicker (McKendrick et al., 2001). They excluded the 
retina to be the origin of theses magnocellular defects when they simultaneously 
recorded retinal and cortical visually evoked electrophysiological responses in-between 
migraine attacks using pattern-reversal electro-retinograms (PERGs) and pattern visual 
evoked responses (PVERs), and found PERG to be normal while defects were detected 
on PVERs (Nguyen et al., 2012, Nguyen et al., 2014).  mfPOP responses are generated 
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mainly through a subcortical pathway with some cortical influence – including an 
enhanced  inhibitory effect – at the level of the Edinger-Westphal nucleus (Barbur, 
1995). If the observed effect of decreased pupillary constriction was due to a direct 
influence from the cortex during cortical spreading depression (CSD), an increased, 
rather than a decreased, contraction would have been observed due to the loss of the 
inhibitory effect on the pupillary pathway leading to pupillary constriction. This was 
the opposite of what occurred. This allows speculation that these changes may arise 
independently from the cortex and that the spreading depression might extend and 
involve a subcortical pathway, namely the pupillary pathway leading to pupillary 
dilatation. 
Although the use of pain-relieving medications in this study may have altered the 
course of migraine and set the migraine brain excitability to a different threshold, the 
fact that patients were allowed to use their own medication permitted assessment of the 
effect of triptan use; interestingly, this was associated with increased pupillary 
constriction. This finding is the opposite of what might have been expected because the 
serotonergic effects of triptan overdose are well known to cause mydriasis. The mfPOP 
system does not use absolute pupil size, but rather changes in pupil size relative to the 
mean and, interestingly, the triptan effect was restricted to some parts of the visual 
field. If the effect of triptans was on the iris as a whole, this should have resulted in a 
global visual field change. The fact that it did not suggests that the triptans could have 
had an effect on cortical hyperexcitability (Coppola and Schoenen, 2012). 
Our study did have some limitations, the subjects included had infrequent migraine 
attacks (mean attacks were 2.6 per month); and we had a short baseline period (only 
two weeks). 
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Conclusions  
This study has demonstrated that stimulation of melanospin-containing ipRGCs did not 
alter migraine severity parameters, and that overall pupillary responses did not differ in 
migraine patients from normal controls. Abnormalities were detected only if testing 
was carried out shortly after an attack or if subjects were taking triptans. mfPOP proved 
to be an important tool in studying visual pathophysiology in migraine subjects and was 
able to map visual field defects and pupil response changes. 
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Abstract  
Aim: To investigate the pattern of pupillary abnormalities in patients with epilepsy 
using Multifocal Objective Pupil Perimetry (mfPOP), and to conduct a preliminary 
investigation of its safety. While the stimuli provided during mfPOP fall well outside 
the usual parameters for epileptogensis, a preliminary investigation is warranted. 
Design/Methods: A cross-sectional, open-labelled, study of 15 consecutive patients 
with epilepsy and 15 controls who underwent mfPOP during routine EEG testing. 
mfPOP responses were obtained from 44 regions of both visual fields simultaneously. 
Each region was analysed according to response time-to-peak and standardised 
amplitude. The proportion of patients developing a seizure, a photo-paroxysmal 
response (PPR), or increased epileptiform activity on their EEG during mfPOP was 
used as the outcome measure of safety. Results: All subjects tolerated mfPOP testing 
well. No patient developed an epileptic aura or clinical seizure during (or shortly after) 
testing. There was no evidence of a PPR or increased epileptic activity in any subject. 
Pupillary responses were larger in patients with generalised epilepsy than in controls by 
a mean of 3.8 dB ± 1.43 dB (mean ± SE), and these changes where perhaps biased to 
the superior field. The use of antiepileptic medication reduced pupillary responses by a 
mean of 4 dB ± 1.74 dB. A mean delay of 24.9 ± 10.2 ms in the time-to-peak of the 
pupillary response was seen in patients with focal epilepsy. Changes in response delay 
seemed to be expressed uniformly across the visual field. 
Conclusions: Performing EEG during testing has provided preliminary evidence of the 
safety of mfPOP in patients with epilepsy. The high level of inter-connectivity of the 
pupillary system with many brain areas means that mfPOP may represent a useful tool 
in the study of epilepsy. 
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3.1.  Introduction   
 
Visual stimuli provoking photic-induced seizures seen on electroencephalography (EEG) 
as a photo-paroxysmal response (PPR) are believed to act through increasing occipital 
cortex excitability. This has been demonstrated using functional MRI (Chiappa et al., 
1999) and trans-cranial magnetic stimulation (Siniatchkin et al., 2007). The pretectal 
olivary nuclei are highly interconnected with many brain areas including the cerebral 
cortex (Gamlin, 2006). These interconnections influence the Edinger Westphal nucleus 
leading to alterations in the pupillary response. How changes in cortical excitability 
might influence the pupillary response in epilepsy patients has not been yet explored. 
Multifocal Pupillographic Objective Perimetry (mfPOP) was introduced about a decade 
ago (Tan et al., 2001, Wilhelm et al., 2000b). More recently, a version with FDA 
clearance has been developed by our group, the nuCoria Visual Field Analyser (nCFA). 
It objectively assesses visual function using the pupillary response and has been 
successfully evaluated in several conditions including diabetic retinopathy (Bell et al., 
2010, Sabeti et al., Sabeti et al., 2015), macular degeneration (Sabeti et al., 2012, Sabeti 
et al., 2014), glaucoma (Carle et al., 2011a, Carle et al., 2015), and multiple sclerosis (Ali 
et al., 2014).  mfPOP is potentially useful in the study of epilepsy by better characterizing 
the pupillary response and we will investigate whether it is influenced by cortical 
excitability or factors that alter that excitability such as anti-epileptic medications. 
Our previous study of mfPOP in migraine (Chapter 2) suggests that mfPOP may quantify 
changes in brain excitability due to either treatment effects or the time since a migraine 
attack (Lueck et al., 2014). Therefore it is reasonable to examine possible effects of 
antiepileptic medication, and also any differential effects of focal versus generalised 
epilepsy in comparison to normal population. 
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Since the mfPOP device delivers fixed-intensity supra-threshold visual stimuli presented 
randomly to various locations in the visual field at a rate of 22 stimuli per second, its 
safety in patients with epilepsy requires investigation. That being said, its stimulus 
parameters fall well outside those expected to be epileptogenic (Harding et al., 2005). 
Over the past 10 years the group has done over 14,000 mfPOP tests on over 3800 adults 
without a report of an epileptic seizure. Over 900 subjects have had 6 or more mfPOP 
tests, where 3 or more tests were done in a single sitting for every subject. 
Current guidelines evaluating the  safety of artificial light-emitting sources in patients 
with photosensitive epilepsy (PSE) rely on comparison against stimulus parameters 
which are known to provoke seizures (Harding et al., 2005). However, these guidelines 
lack objective proof of the safety of the individual sources. We were interested to see if 
mfPOP produced signs of epileptogenesis in actual epilepsy patients using 
electroencephalography (EEG) and investigate its tolerability during perimetric testing.  
Our study was carried to investigate the pattern of pupillary abnormalities in patients 
with epilepsy using mfPOP, and to conduct a preliminary investigation of its safety in 
the same population of patients 
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3.2.  Methods  
 
3.2.1. Study Design 
 
This cross-sectional, open-labelled study was conducted at The Canberra Hospital, 
Canberra, Australia. The primary endpoint was the proportion of patients developing 
any of the following:  aura/seizure during (or shortly after) testing, a photo-paroxysmal 
response (PPR), or increased epileptiform activity on the EEG during mfPOP testing. 
Secondary endpoints included establishing the pattern of mfPOP abnormalities in 
patients with epilepsy. 
The study conformed to the Declaration of Helsinki guidelines and approval from both 
the human research ethics committee of the Australian National University (protocol 
2012/303) and the ACT Health Human Research Ethics Committee (ETH 4.12.080) 
overseeing The Canberra Hospital was obtained.  Informed written consent was 
obtained from all subjects. 
 
3.2.2. Subjects 
 
Successive patients undergoing routine clinical EEG were enrolled. Participants were 
18 years of age or older divided into: 1) subjects, if they had a clear diagnosis of 
epilepsy by history and medical records; or 2) controls, if they were being evaluated by 
EEG for other reasons such as syncope or psychiatric illness.  Exclusion criteria 
included pregnancy or breast feeding, a seizure occurring within the previous 24 hours, 
a history of other visual or neurological disturbance that might affect visual assessment, 
and consumption of medication that could interfere with pupillary responses.  
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3.2.3. Study settings and procedures  
 
All participants underwent routine EEG testing with activity recorded from 19 scalp 
electrodes according to the international 10-20 system (1958). The EEG protocol 
included standard provocation techniques of hyperventilation and intermittent photic 
stimulation (IPS).  After completion of the standard EEG (30 min) subjects were placed 
in a sitting position and were asked to look into the mfPOP device. The electrodes 
remained attached and EEG recording continued during mfPOP testing.   
 
3.2.4. mfPOP stimulation 
 
mfPOP responses were obtained using a nuCoria Field Analyser® (nCFA) prototype 
(nuCoria Pty Ltd, Canberra, Australia) as described in Chapter 1 (Figure 1) . In 
summary, subjects viewed liquid crystal displays (LCDs) provided independent stimuli 
to each eye separately out to 30° eccentricity. Corrective lenses were supplied as 
necessary. Forty-four regions per visual field were tested with yellow stimuli exhibiting 
peak luminance ranging from 138.2–290.0 cd/m2, the luminances being selected to 
generate approximately equally reliable responses from each visual field location. The 
background illumination was 10 cd/m2. Pseudo-randomly sequenced stimuli were 
presented independently to each eye (i.e. dichoptic stimulation) resulting in 44 
independent direct and consensual pupillary responses/eye. Each of the pulsed stimuli 
lasted for 33 ms and stimuli were separated by an average inter-stimulus interval of 4 
seconds, thereby providing a mean presentation rate of 22 stimuli/s. Each measured 
response was thus the average for 90 stimulus presentations. The test period was 
divided into nine segments of 40 seconds (6 min total). Infrared video cameras 
measured pupil diameter. 
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Figure 1. Measurement of pupillary responses. A) Schematic of the nuCoria Field 
Analyser®. Stimuli are presented independently on two LCD monitors (a). These 
images are reflected by two dichroic mirrors (b) allowing infrared light to pass while 
reflecting shorter wavelengths. Viewing distance is increased to optical infinity by 
plano-convex lenses (c). Each eye views only one monitor, the images being fused by 
the subject into a cyclopean view. Infrared illumination of the eyes is provided by 
infrared light-emitting diodes (d) facilitating the monitoring of each pupil by separate 
infrared video cameras (e). Pupil diameters are then extracted in real-time and recorded 
by a computer (f). B) The 44 stimulus regions per eye were arranged in a dartboard-like 
polar layout extending to 30° from fixation. C) Showing the independent stimuli 
(dichoptic) from a series of video frames of the test sequence. Stimuli were pseudo-
randomly presented to each hemifield of each eye in a consecutive series.  
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3.2.5. Data analysis 
 
EEG interpretation was undertaken independently by experienced neurologists. mfPOP 
analysis was conducted using MATLAB software (MathWorks, Natick, MA, USA). 
Baseline characteristics (age, gender) were compared between patients and controls 
using Student’s t-test and chi-square, respectively. Fisher’s exact test was used to 
compare the proportion of subjects developing any of the primary outcome measures 
before and after mfPOP testing.  
For the secondary outcome measures, a total of 176 response waveforms per subject for 
both direct and consensual responses were obtained and these were then fitted to a log-
normal function as described elsewhere (Bell et al., 2010, Carle et al., 2011a). Each 
regional response was analysed for deviation from normal according to response time-
to-peak (TTP), expressed in milliseconds (ms), and standardized amplitude (AmpStd), 
expressed in decibels (dB) (Figure 2). AmpStd was used to overcome inter-subject 
variation in mean pupil diameter: it assessed changes in pupil size after correcting to 
the mean diameter of the population rather than using absolute pupil size.  
The effects of multiple epilepsy parameters on pupillary characteristics were examined 
using multivariate linear models. These parameters included seizure type (generalized 
vs. focal), family history of epilepsy, light already identified as trigger for epilepsy, 
gender, age, and consumption of antiepileptic medications.   
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Figure 2. Example mfPOP response waveforms from an individual subject (above). 
The mean pupil responses to stimuli present to each of the 44 test regions were obtained 
from both eyes concurrently from 6 minutes of stimulation. Downward deflection 
indicates contraction. The red and green traces are the responses of the left and right 
pupils. (Below) Pupil responses are analysed according to amplitude and delay (time to 
peak). 
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3.3.  Results  
 
3.3.1. Demographics  
 
A total of 15 subjects (8 males; mean age ± SD 47.3 ± 4.6 years), including three with 
known photic induced seizures, and 15 controls (9 males; mean age 52.7 ± 4.6 years) 
were studied. There were no significant differences between the two groups regarding 
either age or gender. In the subject group, 11 had generalized epilepsy and seven had 
focal epilepsy according to the ILAE classification (Berg et al., 2010), three patients 
had both types. Eleven subjects were taking antiepileptic medications. In the control 
group, three individuals were taking antiepileptic medications, two as a mood stabilizer 
and one in case a diagnosis of epilepsy was not confirmed. Antiepileptic medications 
included carbamazepine, oxcarbazepine, valproic acid, phenytoin, lamotrigine, 
levetiracetam, gabapentin and pregabalin. There were no differences in the median 
baseline absolute pupil sizes for controls and epileptics which were 3.59 ± 0.623, and 
3.56 ± 0.326 mm (median ± SD). 
3.3.2. Safety of the mfPOP device  
 
Both subjects and controls tolerated mfPOP testing well. None developed clinical 
seizures, aura, or PPR on EEG. Prior to mfPOP testing, four subjects from the epilepsy 
group showed evidence of epileptiform activity on EEG with one subject developing 
electrophysiological subclinical seizure activity starting before mfPOP testing. This 
activity continued during and after mfPOP testing, but there was no sign of 
exacerbation by the perimetry. Otherwise, there was no evidence of abnormality on 
EEG during the mfPOP testing segment in any of the subjects or controls.  
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3.3.3. Abnormalities detected by mfPOP 
 
3.3.3.1. AmpStd:  
 
The mean AmpStd across test regions (Table 1A) for the control group was 19.8 
± 1.1 dB (mean ± SE). For patients with generalized epilepsy, a significant increase of 
3.8 dB ± 1.43 dB in AmpStd (p = 0.01) was seen, i.e. a 2.40-fold increase (95% CI: 
1.26 - 3.31) compared to controls. The use of antiepileptic medication reduced AmpStd 
by 4.0 dB ± 1.74 dB (p = 0.02), i.e. a 2.53-fold reduction (95% CI:  1.14 - 5.65). There 
was no effect of focal epilepsy, family history of epilepsy, light previously identified as 
trigger for epilepsy, gender, or age. The gray-scale plots (Figure 3A, 3B) demonstrated 
enhanced sensitivity (increased AmpStd) above the equator relative to controls in the 
generalized epilepsy group (p < 0.05) with an inferior-to-superior gradient. The focal 
epilepsy group only showed mild suppression of sensitivity, especially inferiorly. 
3.3.3.2. Time-to-peak:   
 
The mean TTP across regions (Table 1B) for controls was 477.5 ± 6.19 ms 
(mean ± SE). A mean increase in TTP of 24.9 ± 10.2 ms was seen in patients with focal 
epilepsy (p = 0.02) but there was no significant increase in patients with generalized 
epilepsy. As previously described in other mfPOP studies (Ali et al., 2014) female 
gender was associated with significantly shorter TTP by about 22 ms. As subjects aged 
their responses slowed by the rate of 9.79 ms per 10 years (also as reported in previous 
mfPOP studies) (Ali et al., 2014). 
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The gray-scale plots (Figure 3C, 3D) showed that the focal epilepsy group (Figure 3D) 
had more regions showing significantly increased TTP compared to the generalized 
group (p < 0.05) (Figure 3C). 
Table 1. Independent effects of patient parameters on AmpStd and Time-to Peak 
A) Independent Effects of Patient Parameters on AmpStd  
 
 
Mean dB ± SE T stat  
P value 
(Two sided) 
Constant*   19.8 ± 1.07  18.5  -  
Generalized epilepsy  3.80 ± 1.43 2.72  0.01  
Focal  epilepsy  1.43 ± 1.76  0.81  0.42  
Anti-epileptics  -4.04 ± 1.74 2.32 0.02 
B) Independent Effects of patient parameters on time-to-peak  
 
Mean ms ± SE T stat  P value  
(Two sided)  
Constant**   477.5 ± 6.19  77.1  -  
Generalized epilepsy  -8.87 ± 8.10  1.09  0.28  
Focal  epilepsy   24.9 ± 10.2  2.44  0.02  
female  -22.1  ± 8.5 2.61  0.01  
Age effect relative to 47 y  
(ms/decade)  
9.79  ± 2.44  4.11  0.001<  
* Independent effects on AmpStd estimated by a multivariate linear model, the factors 
were fitted as contrasts to a reference value termed a constant which is the mean 
response in dB for the control group.  The values of the other factors thus represent the 
differences from the constant (strictly the global mean for male control subjects aged 47 
years) and the significances of those differences, and their t- and p-values. For the 
103 
 
constant (reference value) the t-static indicates its significance relative to a response of 
0.   
** A similar model was used and the Constant for time-to-peak constituted the mean 
response time-to peak in milliseconds (ms) from all regions of both eyes and both direct 
and consensual responses of the control group. When compared to the constant positive 
values will indicate a slower time-to-peak, i.e. additional delay. 
 
 
 
 
 
 
 
Figure 3. Gray scale plots. The top row are the controls and the bottom plots are 
the differences from the controls for the cases described and all the numbers come 
from a single multivariate model.  The top row (A, B) represented the mean region-
by-region contraction AmpStd deviations from controls in the generalized epilepsy 
group (A) and focal epilepsy group (B); n.b. lighter regions represent increased dB 
sensitivity compared to control values, darker regions reduced sensitivity.  
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The bottom row (C, D) shows mean contraction time-to-peak deviations from controls 
in the generalized epilepsy group (C) and focal epilepsy group (D). The darker regions 
represent faster TTP than control values, brighter regions indicate longer TTP.  
For all panels the background grey represents 0 change compared to controls. 
 
3.4.  Discussion  
 
This study has demonstrated an enhancement of the pupillary contractions in the form 
of increased pupillary response standardized amplitudes in patients with generalized 
epilepsy, an effect which appears to be reversed by antiepileptic medication. In 
addition, the time-to-peak of the pupillary response was increased in patients with focal 
epilepsy. This study has also added to data on the safety of the mfPOP device in 
patients with epilepsy, determined both clinically and electro-physiologically. 
This is believed to be the first study to examine and characterise the pupillary response 
in patients with epilepsy during the interictal phase. The enhanced pupillary 
constriction observed in the generalized epilepsy group could be due to altered 
autonomic function, something which has been reported to cause either pupillary 
mydriasis or miosis during the ictal phase as part of general autonomic nervous system 
inhibition or activation. Alternatively, the overactive pupillary responses could be part 
of a more generalized cortical excitability which is associated with generalized 
epilepsies (Badawy et al., 2014). Disturbance in the neuronal excitatory/inhibitory 
balance leading to the formation of hyper-excitable seizure networks is an important 
proposed mechanism underlying the pathophysiology of epilepsy (McCormick and 
Contreras, 2001). Alterations in cortical excitability have been observed for 24, and 
even up to 48, hours before and after seizures. In addition, several factors have been 
found to alter this excitability including menstrual cycle, time of day, sleep and sleep 
deprivation, possibly explaining why these factors are considered to be epilepsy 
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triggers in themselves (Badawy et al., 2012). About half of the input to the Edinger-
Westphal nucleus arises from the extrastriate cortex (Gamlin, 2006).This cortical 
influence is believed to be inhibitory in nature based on studies showing that when 
transcranial magnetic stimulation was placed over the occipital cortex in humans it 
inhibited the pupil constriction elicited by a light stimulus given to the retina, although 
not causing  pupillary dilation (Kardon, 2005 ). In the light that generalised epilepsy 
subjects do have increased cortical excitability this should have led to inhibition of the 
parasympathetic pupillary response, thus leading to pupillary dilatation. This is to the 
contrary to what we found, making us speculate that pupillary response exhibit a 
subcortical excitability independent from cotical influence. Whether this overactivity 
also contributes to photosensitivity in patients with generalized epilepsy needs further 
exploration (Wolf and Goosses, 1986). Comparing these results to our results in 
migraine patients - which is another disorder believed to exhibit cortical 
hyperexcitability- we found that shortly after an attack there was a reduction in 
pupillary contraction, which was believed to be due cortical spreading depression 
occurring during and shortly after migraine attacks. If we also considered a decrease in 
cortical influence over the pupillary response in that situation we would speculate a loss 
of inhibition and thus increased pupillary constriction like what is observed in fatigue 
and drowsiness in humans and in animals (Kardon, 2005 ) ,yet we saw the opposite 
effect further supporting the notion that the changes in the pupillary response 
excitability is independent from cortical influence. 
The use of antiepileptic medication led to a reduction of the pupillary response. Many 
antiepileptic medications have anticholinergic activity which would be expected to lead 
to pupillary dilation and/or reduced constriction. On the other hand, cortical hyper-
excitability has been shown to be decreased in patients taking antiepileptic medications 
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(Badawy et al., 2010) and this may account for the observed reduction in pupillary 
response. Future research is needed to clarify this issue and there may be implications 
for the selection of medication used for treating patients with photosensitive epilepsy. 
Furthermore in the coming chapter (Ali, 2016) we will study the interaction between 
the alpha rhythms on the EEG and the photic stimulation and how they affect mfPOP 
pupillary parameters, this will further  reinforce the role of mfPOP characterise changes 
of cortical excitability. 
The explanation for the increase in time-to-peak of the pupillary response in patients 
with focal epilepsy is not clear. One possibility is that structural abnormalities, which 
are known to be more common in focal seizures, have altered structures involved in the 
pupillary pathway.  
A consensus view of stimuli likely to provoke visually-evoked seizures has been 
proposed by the Epilepsy Foundation of America (Harding et al., 2005). Although 
guidelines exist for  commercial television broadcasters in some countries (Harding and 
Takahashi, 2004), there is no  definite objective evidence that implementing these 
guidelines actually prevents clinical or subclinical events.  Similarly, there is no 
standardised protocol for testing light-emitting medical devices. A logical step would 
be to assess safety of all medical light-emitting devices using EEG testing in the way 
that this study did to demonstrate the safety of the mfPOP device in epilepsy; however, 
the small sample size and the fact that no patient demonstrated a clear PPR on EEG 
during routine IPS are limitations to our study. The demonstration of a PPR during IPS 
but not during the mfPOP would have provided stronger evidence of safety. This would 
have been difficult to achieve  since the chance a person referred to an EEG lab from 
the population develop PPR is only 2.8 /100 regardless of the diagnosis (Jeavons and 
Harding, 1975).  
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Our study had limitations in the form of small sample size and the control group not 
consisting of healthy volunteers instead they were subjects with disorders other than 
epilepsy referred to the neurophysiology lab for EEGs, but who had been shown to not 
have epilepsy. 
In conclusion, standardization of testing light emitting medical devices is of importance 
when assessing their safety in patients with photosensitive epilepsy. More studies 
looking at changes in the pupillary response in the interictal phase are needed. 
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Abstract  
Purpose: Photic drive responses (PDRs) have been used to explore cortical hyper-
excitability in neurological disorders. We quantified changes PDR in epilepsy patients 
and looked for interactions with responses obtained from multifocal objective 
pupillographic perimetry (mfPOP).  
Methods:  This was a cross-sectional study of 15 consecutive epilepsy patients (mean 
age ± SD 47.3 ± 4.6 years; 8 males), and 15 controls (mean age 52.7 ± 4.6 years; 9 
males) undergoing routine EEG with standard intermittent photic stimulation (IPS), and 
testing with the mfPOP device. EEG spectral amplitudes during IPS were obtained 
using the discrete Fourier transform. N-fold changes in PDR (expressed in dB) when 
IPS and alpha bands overlapped: the alpha-band gain, were examined and also their 
interaction with mfPOP responses. Alpha-band gain was determined by comparing 
eyes-open and eyes–closed conditions, with and without IPS. mfPOP responses were 
obtained from 44 regions/visual field. Response time-to-peak and standardized 
amplitude was recorded for each test region.  
Results: A linear model indicated that an epileptic attack within 1 month increased the 
alpha-band gain by 1.33 dB (p=0.01). Generalised epilepsy (i.e. no focal epilepsy) 
decreased the alpha-band gain by -1.03 dB (p=0.03). For each decade increase in age 
the gain increased by 0.36 dB (p=0.007). For every 1 dB increase in alpha-band gain 
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pupil responses were reduced by 0.21 ± 0.09 dB on average across the field (p=0.024). 
Conclusions: Investigating alpha-band gain offers another way to quantify cortical 
hyper-excitability in epilepsy patients. Responses to mfPOP may provide less invasive 
means to quantify hyper-excitability. 
 
4.1.  Introduction  
 
Intermittent Photic stimulation (IPS) is the most commonly used method of cerebral 
activation for routine electroencephalogram (EEG) examinations. Its effects  on the 
human EEG are reported to have been first noticed by Adrian and Matthews (Schomer 
and Lopes da Silva, 2005). Since then this technique has been validated as a useful 
activation method for eliciting paroxysmal EEG activity (Walter et al., 1946). The three 
main EEG changes induced by IPS are: 1) Photo-entrainment or Photic drive response 
(PDR); 2) the Photoparoxysmal response (PPR); 3) and the Photomyoclonic response 
(Schomer and Lopes da Silva 2005). The latter two have been associated with epilepsy 
whereas changes in the PDR are less explored in epilepsy patients.  
PDR is a physiologic response consisting of rhythmic activity time-locked to the 
stimulus at a frequency identical or harmonically related to that of the stimulus 
(Noachtar et al., 1999). The sources of the PDR are not fully understood. It was 
believed to occur as a result of a flash visual evoked response. This was supported by 
the fact that the background rhythm becomes synchronised to the timing of the photic 
stimulator with the first response appearing shortly after the start of the stimulation 
(<100ms), and stopping when the stimulator stops (Blum and Rutkove, 2007). 
However, this view does not explain why IPS induces not only responses at the 
fundamental frequency, but also other harmonic responses in higher frequency bands 
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(Kikuchi et al., 2002). A simple possibility is just that the stimulus response function of 
the evoked potential is nonlinear, resulting in harmonic responses. Another view has 
been suggested: that the origin of the alpha rhythm is the output of a non-linear 
oscillator that can be entrained by forced stimuli at nearby frequencies. This could only 
happen if the system generating the alpha rhythm was non-linear rather than a narrow-
band transmission system acting as a linear filter (Wiener, 1961). This idea was further 
supported by Gebber et al using analysis in the time and frequency domains showing 
that the alpha rhythm can be entrained to the second or third harmonic of low frequency 
light flashes (3 to12 Hz) (Gebber et al., 1999). Vogel et al. suggested the addition of a 
central adrenergic effect contributing to the generation of PDR when it was found that 
monoamine oxidase inhibitors inhibited the PDR (Vogel et al., 1974). 
The PDR has been studied in migraine patients using the “H response”, which refers to 
an increased tendency of EEG rhythms to synchronize to external repetitive stimuli 
with stimulation frequencies around 20 Hz (Golla and Winter, 1959). This response 
was suggested to reflect a state of cortical hyper-excitability (Simon et al., 1982) and 
was able to distinguish migraine from normal subjects and other headache types with 
reasonable sensitivity and specificity (Fogang et al., 2015, Chorlton and Kane, 2000). 
Other disorders in which PDR has been studied include schizophrenia (Jin et al., 1995, 
Jin et al., 1990) and Alzheimer’s disease (Kikuchi et al., 2002), both of which were 
found to produce PDRs that were distinguishable from normal controls. Changes in 
PDR in epileptic patients have only been evaluated in a few reports, specifically in 
combination with transcranial Doppler sonography to assess posterior circulation blood 
flow in epilepsy patients (Diehl et al., 1998), and in evaluating alcohol-induced seizures 
(Sand et al., 2010). 
113 
 
Our basic aims were to investigate the changes in PDR in epilepsy patients using 
spectral analysis and to search for clinical correlates of abnormal photic driving such as 
type of epilepsy, medication consumption, and recent attacks. We also wanted to see 
whether increased sensitivity of the pupillary response may contribute to a larger 
magnitude of entrainment so we studied whether pupillary response parameters 
obtained from the multifocal objective pupillographic perimetry (mfPOP) was 
correlated with the PDR. 
 
4.2.  Methods  
 
4.2.1. Subjects and settings 
 
Successive patients undergoing routine clinical EEG at the Canberra hospital, Canberra, 
Australia, were enrolled. Participants were 18 years of age or older and were divided 
into: 1) study subjects, if they  had a clear diagnosis of epilepsy by history and medical 
records, or 2) controls, if they were being evaluated by EEG for other reasons such as 
syncope or psychiatric illness.  Exclusion criteria included pregnancy or breast feeding, 
a seizure occurring within the previous 24 hours, a history of other visual or 
neurological disturbance that might affect visual assessment, and consumption of 
medication that could impair pupillary responses. The study conformed to the 
Declaration of Helsinki guidelines and approval from both the Human Research Ethics 
Committee of the Australian National University (protocol 2012/303) and the ACT 
Health Human Research Ethics Committee (ETH 4.12.080) was obtained.  Informed 
written consent was obtained from all subjects 
  
4.2.2. mfPOP stimulation and recording 
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All subjects underwent mfPOP assessment using the nuCoria Field Analyser® (nCFA) 
prototype (nuCoria Pty Ltd, Canberra, Australia), which has FDA 510k clearance. The 
components of the device are summarised in (Figure 1A). Corrective lenses 
compensated for refractive errors. Stimuli were produced by a pair of LCD displays and 
reflected by cold dichroic mirrors. Forty-four individual stimuli were arranged in a dart-
board like pattern extending to ± 30°eccentricity of visual field (Figure 1 B, C). To 
reduce the effects of possible light scatter from adjacent regions a background 
illumination of 10 cd/m2 was used to adapt rod photoreceptor responses. Stimuli were 
presented dichoptically (independently) to both eyes concurrently, and the dynamic 
diameter of each pupil was recorded by infrared video cameras at 30 / s under infrared 
illumination. The appearance of individual stimuli was governed by pseudo-random 
sequences that allowed the average response at each test region to be estimated by 
multiple regression (Carle et al., 2013). The stimulus and recording arrangement 
resulted in direct and consensual responses from each tested visual field region. 
Relative (rather than absolute) pupil diameter was recorded and transformed to 
standardised amplitudes of a 3.5 mm pupil (Bell et al., 2010). Only the lower 75% 
portion of the pupil was recorded to avoid problems generated by ptosis. Up to 15% 
data loss from blinks and fixation loss was permitted. If more than 15% was lost, that 
particular recording segment was repeated. The standard mfPOP testing protocol 
involved stimuli with a maximum luminance of 150 cd/m2 and stimulus duration of 33 
msec. Test duration for both eyes was 6 minutes. 
For the pupillary response analysis, a total of 176 response waveforms per subject (2 
eyes × 2 pupils × 44 regions/eye) for both direct and consensual responses were 
obtained and these were then fitted to a log-normal function as described elsewhere 
(Figure 2) (Carle et al., 2011a, Carle et al., 2013). Each regional response was then 
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analysed for the amount of deviation from normal according to response time-to-peak 
(TTP), expressed in milliseconds (ms), and standardized amplitude (AmpStd), 
expressed in decibels (dB). 
 
 
Figure 1.  Measurement of pupillary responses. A) Schematic of the nuCoria Field 
Analyser®. Stimuli are presented independently on two LCD monitors (a). These 
images are reflected by two dichroic mirrors (b) allowing infrared light to pass while 
reflecting shorter wavelengths. Viewing distance is set to optical infinity by plano-
convex lenses (c). Each eye views only one monitor, the images being fused by the 
subject into a cyclopean view. Infrared illumination of the eyes is provided by infrared 
light-emitting diodes (d) facilitating the monitoring of each pupil by separate infrared 
video cameras (e). Pupil diameters are then extracted in real-time at 30 / s and recorded 
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by a computer (f). B) The 44 stimulus regions per eye were arranged in a dartboard-like 
polar layout extending to 30° from fixation. C) Showing the independent stimuli 
(dichoptic) from a series of video frames of the test sequence. Stimuli were pseudo-
randomly presented to each hemi-field of each eye in a consecutive series. A faint 
background starburst pattern assists the subjects to fuse the images. 
 
 
 
 
 
 
 
 
Figure 2. Example mfPOP response waveforms from an individual subject. The 
mean pupil responses to stimuli present to each of the 44 test regions were obtained 
from both eyes concurrently from 6 minutes of stimulation. Downward deflection 
indicates contraction. The black and grey traces are the responses of the left and right 
pupils. 
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4.2.3. EEG Intermittent photic stimulation protocol 
 
Each subject underwent a total of 20 minutes of EEG recording. A total of 26 
electrodes were placed according to the 10-20 system and included channels for 
recording horizontal and vertical eye movements and electrocardiograph. The EEG was 
recorded digitally using ProFusion EEG software version 4.3 (Compumedics, 
Abbotsford, VIC, Australia). The sampling rate was 250/s. The band pass filter setting 
was 0.5-70 Hz with a notch filter at 50 Hz. In a dimly lit room, Intermittent Photic 
Stimulation (IPS) was delivered toward the end of the recording with subjects lying in a 
semi-supine position 30 cm away from the photo-stimulator stroboscope 
(Compumedics Neuroscan Model 7097).  The stimulus frequencies were 2, 4, 6, 8, 9, 
10, 11, 12, 13, 14, 15, 18, 20, 25, 50 flashes/s. EEG recordings were exported using the 
European Data Format (EDF) and analysed using MATLAB software (MathWorks, 
Natick, MA, USA). Most analysis presented here was restricted to the occipital 
responses (O1 and O2).   
Each frequency was delivered as a 10 seconds (s) train divided into 5 s with the eyes 
closed followed by the eyes being opened for the further 5 s. This was followed by a 10 
s inter-train interval break. The eyes remained closed for the first 5 s of the break period 
and then open for the final 5 s and EEG recording continued throughout. The 
nomenclature for these stimulus conditions is given in (Table 1A), and their sequence 
118 
 
is given in (Table 1B).  After the 20 min of IPS testing subjects were placed in the 
sitting position and were asked to look into the mfPOP device for testing. 
 
 
 
Table1A. Epoch definitions   
Definition 
 
Epoch name 
 
eyes open (EO) with Intermittent Photic Stimulation 
(IPS),  
which includes a visual evoked potential (VEP)  
EOwith IPS 
eyes closed (EC) with IPS, 
which includes the photic drive response (PDR) ECwith IPS 
eyes closed (EC) without IPS,  
which includes the baseline alpha rhythms ECwithout IPS 
eyes open (EO) without IPS or alpha rhythms 
 EOwithout IPS 
  
 
Table1B. Repeated epoch sequence, each of epoch 1 to 4 was 5 seconds in 
duration   
Epoch 4 Epoch 3 Epoch 2 Epoch 1  
EOwithout IPS ECwithout IPS ECwith IPS EOwith IPS Epoch name 
Open Closed Closed Open Eyes 
 √ √  alpha 
rhythm 
  √ √ IPS 
  
 
 
To quantify any interactions between the VEP and the alpha band we calculated the 
alpha-band gain, which is the N-fold change in the VEP when it occurs with the alpha 
band for each stimulus frequency F, and also for its harmonics (F/2, 2F, 3F, 4F) as 
follows:- 
1) Alpha band gain = ECwith IPS – ECwithout IPS / EOwith IPS – EOwithout IPS 
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Where EC with IPS – EC without IPS represents: PDR – baseline alpha band; 
and EOwith IPS – EOwithout IPS represents: VEP – background noise. Hence equation 1 can 
be written:- 
2) Alpha Band Gain = (PDR – baseline alpha band)  / ( VEP – background noise) 
Of course the “baseline alpha amplitude” includes noise. Thus, the alpha-band gain 
characterises the N-fold change in the PDR relative to the VEP independent of noise 
and alpha-band strength. The alpha-band gain was calculated for all subjects: controls 
and epileptic patients. Additionally, groups selected for sub-analyses included all 
subjects on anti-epileptic medications, controls on anti-epileptics, epileptic subjects on 
anti-epileptics, subjects with focal epilepsy, and subjects with generalised epilepsy. We 
also examined the gain for all subjects not on anti-epileptics, controls not on anti-
epileptics, epileptics not on anti-epileptics, and subjects with  an epileptic attack in the 
last 2 months or less prior to recording. 
4.2.4. Statistical analysis 
 
Analysis of the mfPOP data was conducted using MATLAB software (MathWorks, 
Natick, MA, USA).  Baseline characteristics (age, gender) were compared between 
patients and controls using Student’s t-test and chi-square tests, respectively. 
Other analysis involved two multivariate linear models. The first examined the alpha-
band gain as a function of explanatory variables that included type of epilepsy, recent 
epileptic attack and age. Here the alpha-band gain was selected to be the mean of the 
gain across the IPS frequencies 9, 10, 11 Hz and was expressed in decibels (dB) in 
order to fit additive models and stabilise the variance. The second model examined the 
effects of explanatory variables on mean pupillary response including alpha-band gain, 
type of epilepsy, and recent attacks of epilepsy. 
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Our basic aims were to explore interactions between the alpha band and the responses 
to IPS, and whether there was any correlation with responses obtained from the 
pupillography. 
4.3.  Results 
 
4.3.1. Demographics  
 
A total of 15 subjects (mean age ± SD: 47.3 ± 4.6 years; 8 males), including three with 
known photosensitivity, and 15 controls (mean age 52.7 ± 4.6 years; 9 males) were 
studied. There was no significant difference between the two groups regarding either 
age or gender (Table 2). At the time of the photic stimulation, four patients had focal 
EEG slowing and three had epileptiform discharges. One control subject had 
generalised slowing. None of the epileptic patients or controls had a photoparoxysmal 
response. 
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Table 2 Demographics  
 
3 patients were described as having both generalized and complex partial epilepsy  
3 patients were on antiepileptics although they were controls either taking it for other 
causes (mood stabilizer such as valoproic acid for bipolar disorder, or suspension till 
diagnosis confirmed to be epilepsy or not  
2 patients only were on 2 antiepileptics  
.  
 
Subjects 
(n=15) 
Controls 
(n=15)  
Age (mean ± SD)  47.3 ± 4.6 52.7 ± 4.6  
Female: male  1 : 0.9 1 : 1.5 
Type of epilepsy 
Generalized  
Focal  
 
11 
7 
- 
Photosensitivity  3 - 
Anti-epileptic medications 
Carbamazepine  
Oxacarbazepine 
Valoproic acid    
Phenytoin  
Lamotrogine  
Levetiracetam  
Gabapentin  
Pregabalin  
11 
1 
1 
2 
2 
1 
4 
1 
1  
3 
- 
- 
1 
- 
- 
2 
- 
- 
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3.2  
Figure 3. Example of the amplitude spectra during intermittent photic stimulation 
(IPS) of an epilepsy patient. The figure also illustrates the eyes-open (EO) and eyes-
closed (EC) epochs and therefore the basis of the alpha-band gain calculations. The red 
and green lines represent the data from O1 and O2 respectively. The abscissa on each 
panel is a log scale where octaves of the frequencies are in equal sized steps. Each test 
is divided into four epochs of 5 seconds duration represented by the four columns. As 
indicated by the column titles the epoch correspond to: eyes open with intermittent 
photic stimulation (EOwith IPS), eyes closed with IPS (ECwith IPS), eyes closed without IPS 
(ECwithout IPS)and eyes open without IPS (EOwithout IPS), see Table 1A and 1B.  
F is the photic stimulation frequency which corresponds to the frequency indicated at 
the end of each row, and its harmonics are indicated as F/2, 2F, 3F, and 4F. The 
ordinate represents the amplitude of the spectra measured in µV.
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4.3.2. Alpha band gain  
 
Each epoch was analysed using a discrete Fourier transformation yielding amplitude 
per Hertz (µV/Hz) spectra. (Figure 3) shows exemplary results from one subject, the 
columns of spectra corresponding to the Epochs of Table 1B. In each panel of Figure 3 
the spectrum is presented on a logarithmic frequency scale on which octaves of the 
stimulus frequencies are equal-sized steps. Thus, F is the photic stimulation frequency, 
the rate of which is indicated by the label at the right end of each row of spectra (e.g. 2 
Hz, 4Hz, etc.).  The sub-harmonic F/2, and 2nd to 4th harmonics (2F, 3F, and 4F) 
indicate nonlinear responses to the photic stimuli. During eyes closed (EC, middle two 
columns of Figure 3) the band of alpha frequencies appears to slide from right to left as 
photic stimulus frequency increases down the rows of the figure. Thus, F is initially 
below the alpha band (e.g. 2 Hz) and, by the bottom of (Figure 3) is above it (e.g. 25 
Hz).  The red and green lines represent the data from O1 and O2 respectively. Clear 
peaks at the stimulus frequency (F), and some second harmonics (2F), are seen in many 
of the spectra during the two IPS phases (EO and EC). 
Column 1 of Figure 3 shows VEP response spectra during the first epoch for the EOwith 
IPS condition. Clear VEP peaks are seen at the IPS frequency from about 6 to 25 Hz (50 
Hz not shown), reaching a maximum of 3.3 µV at around 14 Hz.  Column 3 shows the 
basic alpha band response spectrum during the third ECwithout IPS epoch, the amplitudes 
of which also did not exceed 3 µV.  
Epoch 2, ECwith IPS, appears to show that when the alpha band and IPS frequencies 
overlap (8-13 Hz) that the PDR response may be larger than the simple sum of the 
alpha and VEP amplitudes. We examined this across the subjects by examining the so 
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called alpha band gain: basically the VEP response less noise divided by the PDR less 
the background alpha amplitude (Equations 1 and 2).  
This was repeated for each IPS frequency and each of its harmonics and the results are 
summarised in (Figure 4). Each bar in (Figure 4A, B) is the mean of responses across 
all subjects and across O1 and O2. The alpha band gain was found to exhibit around a 
three times N-fold change (Figure 4C, *), indicating that this was a synergistic (super-
linear) interaction between the VEP and the alpha generator, and not just an additive 
effect. This gain was not apparent for pairs of electrodes away from the occipital pole 
like F7 and F8 (not shown). Interestingly there was also a spike in gain for the 2F 
frequencies for lower IPS input frequencies (Figure 4, +), i.e. when the second 
harmonic of the VEP overlapped with the alpha band. This would indicate that the 
actual interaction is between the output response from IPS and the alpha activity, rather 
than the input IPS frequency and the alpha band. These effects were not observed for 
electrodes F7 and F8. 
 
When looking at specific subject groups (Figure 5) it appeared that the alpha band gain 
was lower in subjects consuming anti-epileptic medications (Figure 5, AntiE), whereas 
not being on this class of medications (Figure 5, EpinoAnti), or having a recent attack of 
epilepsy within the month preceding testing (Figure 5, Recent) both increased alpha 
band gain.  
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Figure 4. All alpha band gains and their derivation. Each vertical bar is a mean 
across all subjects for a particular IPS frequency and harmonic. A) Represents the mean 
EO with IPS – EO without IPS (= VEP- background noise) for each photic frequency F 
(coloured bars) and its harmonics. B) Represents EC with IPS – EC without IPS (= PDR – 
background alpha). C) Shows the alpha band gains, which are each the ratio of EO with 
IPS – EO without IPS / EC with IPS – EC without IPS. 
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Figure 5. Mean alpha band gain for computed for different subgroups. Each row 
was derived as for Figure 4C. The subgroups included were from the top down: control 
subjects (Controls), all subjects on anti-epileptics (AntiE),  all epileptics (Epi), epileptic 
subjects not on anti-epileptics (EpinoAntiE), subjects with an epileptic attack in the month 
prior to recording (Recent), and patients with focal epilepsy (efo). The * indicates 
responses at the driving frequency (F), and a + indicates an IPS 2nd harmonic that 
overlaps with the alpha band. 
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The effect of a recent attack is illustrated more clearly in (Figure 6) where a histogram 
of the gains for individuals was broken-down by the nine subjects who had a recent 
attack of epilepsy less than a month before testing all nine subjects with recent epilepsy 
had an alpha band gain larger than the reference alpha band. This is further seen in 
(Table 3) where the multivariate linear model that assessed the factors affecting the 
alpha band gain showed that recent epileptic attack increased the alpha band gain by 
1.33 dB (p=0.01). Generalised epilepsy decreased the gain by 1.03 dB (p=0.03), and for 
each decade increase in age from controls the gain increased by 0.36 dB (p=0.007). 
 
 
 
 
Figure 6.  Histogram of the alpha band gains for individuals was broken-down by 
the nine subjects who had a recent attack of epilepsy less than a month before testing 
(open bars) and those who had had none (dark bars). 
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Table 3. Alpha band Gain as a function of explanatory variables  
dB ±SE t-stat p 
Controls 0.784  ±  0.27 2.878 0.008 
Generalized 
epilepsy 
-1.027 ±  0.44 2.325 0.029 
Focal epilepsy -0.155 ±  0.46 0.341 0.736 
Recent attack 
(<1 month) 
1.33    ±  0.48 2.76 0.011 
Age  dB/decade * 0.356  ±  0.12 2.911 0.007 
 
*Age is relative to the mean of 47 years. The dB/decade indicates that the gain 
increases by 0.356 dB for each decade increase in age. 
 
 
 
 
 
Table 4. Effect of explanatory variables on mean pupil response AmpStd 
                           (dB) ± SE t-stat p 
Controls                          12.3 ± 0.24 51.006 0.0000
Generalized   epilepsy 0.80 ± 0.2 3.997 0.0001
Focal epilepsy 0.24 ±0.23 1.038 0.301 
Recent Attack 
(<1 month) 
0.99 ± 0.24 4.091 0.0001
Alpha Gain    dB/dB*    -0.21 ± 0.09 -2.294 0.024 
 
* dB/dB means that for every 1 dB increase in alpha gain meant pupil responses are 
reduced by 0.21 dB 
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4.3.3. MfPOP responses  
 
The increase in alpha band gain reduced the mean pupillary response AmpStd, i.e. 
produced less pupillary constriction (Table 4). For each 1 dB increase in the alpha band 
gain the pupillary response was found to drop by -0.21 dB (p=0.024).  Generalised 
epilepsy and recent attacks of epilepsy both significantly increased the AmpStd by 0.8 
and 0.99 dB respectively. 
The grey-scale plots of the average effects on the visual field position for both 
amplitude of the pupillary response (Figure 7) demonstrated enhanced sensitivity 
relative to controls in the recent attack of epilepsy group. For epilepsy types (both 
generalised and focal epilepsy) there was suppression of sensitivity especially inferiorly 
with a possible inferior-to-superior gradient. The data for the colour maps were derived 
from a linear model and so the results for each group are the estimated independent 
effects of general or focal epilepsy and recent attacks. 
The grey-scale plots for the delays in the pupillary response (Figure 8) showed that the 
focal epilepsy group had more regions showing significantly increased time-to-peak, 
and recent attack of epilepsy had an earlier time to peak compared to the controls. 
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Figure 7. Grey scale plots for mean region by region contraction AmpStd 
deviations from controls (top) in the generalized epilepsy,  focal epilepsy groups, and 
subjects with recent attack (<1 month). The lighter the region the more increased 
pupillary response amplitude deviations from control values. Note that for the bottom 3 
panels the background grey represents 0 change relative to normal. 
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Figure 8. Grey scale plots for mean contraction time-to-peak deviations from 
controls in the generalized epilepsy, focal epilepsy groups and subjects with recent 
attack. The lighter regions represent larger delays deviations from controls. 
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4.4.  Discussion 
 
Frequency analyses of EEGs from epilepsy patients and normal controls provided 
evidence of a synergistic interaction existing between responses to the IPS at F and 2F 
and the alpha frequencies when the two coincided. This lead to augmented PDRs, 
which exceeded the simple summation of the VEP response and alpha signal at the 
interaction frequencies. Further augmentation was seen in epilepsy subjects especially 
with a history of a recent attack (Figure 5 and 7, Table 3). A decrease in this 
interaction was observed in subjects consuming anti-epileptic medications and subjects 
suffering from generalised forms of epilepsy. The pronounced IPS and alpha frequency 
interaction had a negative effect on pupillary constriction at 0.21 dB of pupil response 
per dB change in alpha band gain (Table 4).   
We observed an increase in PDR of epilepsy patients that is similar to what has been 
reported in migraine patients (Golla and Winter, 1959, Bjork et al., 2011, Fogang et al., 
2015). Both disorders are believed to share a common interictal cortical hyper-
excitability state. We have also recorded mfPOP responses in migraineurs, reporting an 
overall suppression of response in patients relative to controls, and further suppression 
in patients who had a migraine within the 2 months before testing (Ali et al., 2015).  
However, our present  results on epilepsy may superficially appear to be contrary to a 
previous study of patients with seizures either due to alcohol or epilepsy showing a 
decrease in the “H response” rather than an increase as seen in migraine patients in 
comparison to control groups (Sand et al., 2010). Importantly those authors stimulated 
at 24 Hz. This held true for recent attack of seizure (regardless of the cause), which was 
also associated with a decreased 24 Hz driving response in their regression models. The 
discrepancy with respect to our results of increased PDR are attributed to 
methodological differences between the two studies where we  have investigated 
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entrainment of the  alpha rhythm to the entire IPS frequencies instead of concentrating 
on  24Hz. In their paper they were also speculated an increase rather than a decrease in 
the reactivity to the 24 Hz photic driving, which would have been more consistent with 
a state of cortical hyperexcitability that is known to accompany epileptic attacks 
(Badawy et al., 2013b). In our case, responses to 25 Hz were quite small (Figure 3 and 
4), and did not generate large gain changes (Figure 5). 
 
Another study by Diehl et al. looked at the photic driving EEG response and photo 
reactive cerebral blood flow in the posterior cerebral artery in controls and in patients 
with epilepsy. (Diehl et al., 1998). PDRs were visually inspected on EEGs and 
classified as a good driving response if a well-discernible, harmonic or subharmonic 
EEG synchronization was seen over more than 80% of the stimulus interval. The 
epilepsy group did not show a higher percentage of good PDR (63.3% in comparison to 
81% in the normal control group). It was expected that the good driving response would 
be accompanied by a higher increase in cerebral blood flow velocities (CBFV) in the 
posterior cerebral artery (PCA). This was expected given that brain activity, 
metabolism and blood flow are coupled, yet the increase in CBFV of the PCA in 
normal controls was found to be higher than in patients with focal epilepsy which may 
indicate that epileptic patients have a reduced coupling between neuronal activation and 
blood flow. Again that study used visual inspection rather than computer based spectral 
analysis. Those findings may explain why in our study the large alpha band gain had a 
negative effect on pupillary constriction, it may be due to decreased blood flow to the 
brain stem - a major part of the pupillary pathway response - which is supplied by 
posterior circulation were the PCA is a branch. Another possibility is pupillary 
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constriction may represent a protective mechanism by the brain to decrease light entry 
through the pupils in cases of exaggerated cortical excitability. 
Looking at results of steady state visual evoked potentials (SSVEP) we observe 
similarities to our results, Tsai et al. used SSVEP to contrast reversing gratings and 
found that amplitudes of visual responses did not saturate at high stimulus contrast in 
generalised epilepsy patients, as it did in the control subjects (Tsai et al., 2011). They 
attributed their findings to abnormalities in neuronal gain control. They defined gain 
control as the machinery by which a system dynamically adjusts its sensitivity to the 
input allowing for a wide input range and keeping the output in an optimal regime. 
They went further to use parametric modelling to show that the abnormality lay in 
reduced inhibition from neighbouring neurons rather than increased excitatory response 
to the stimulus. (Geller et al., 2005). 
Both the use of anti-epileptic medications and seizure frequency have been reported to 
affect cortical hyper-excitability (Badawy et al., 2013a) and thus as expected they 
negatively influenced the amplitude of the alpha band gain. The findings here of the 
generalised epilepsy group having a low alpha band gain was not expected and may be 
attributed to the consumption of anti- epileptic medications. Again our results were 
similar to the SSVEP results, when spectral amplitudes were compared between 
controls, focal, and generalized epilepsy groups (Geller et al., 2005). The maximum 
amplitude of the fundamental (F1) component of the VEP was shifted to lower 
frequencies in the generalised epilepsy group relative to the other two groups. Again 
the authors attributed this to reduced intracortical inhibition in the subjects with 
generalized epilepsy.  
 We also found that increase in age led to an increase in the alpha gain which is difficult 
to explain since with age the response to photic stimulation would be expected to 
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decrease rather than to increase (Ross et al., 1997). This may have been a function of 
our particular subjects. 
mfPOP gave us an advantage over full-field pupil responses when studying PDR and 
alpha rhythm changes, A better exposition of this point that while (Table 4.) shows no 
effect upon the mean response amplitude in Focal epilepsy subjects, but there was 
clearly a gradient of amplitude changes in that group as shown in (Figure 7). The 
gradient goes from positive in the superior field to negative in the inferior field, so on 
average there was no effect. Clearly measuring a pupil response to a single large 
stimulus would be akin to assessing the mean response as in (Table 4.) Hence the 
regional analysis afforded by mfPOP was obviously the better approach. 
Limitations of our study include the heterogeneity of our control group with some of 
them having psychiatric disorders such as schizophrenia, which has been shown to  
lower PDR, particularly in the high alpha frequency band (Jin et al., 1990, Jin et al., 
1995), and some being on anti-epileptic medications.  Another limitation is that the 
EEG channels used were according to the 10-20 system, inclusion of an electrode at 
Oz, which generally has the largest VEP response, would have been useful. Yet in a 
previous study (Sabeti, 2010) the same apparatus was used to record multi focal visual 
evoked potentials (mfVEPs), but with a denser 10-10 lay-out showing no real 
advantage could be cited. The timing of the mfPOP was after the 20 minutes of EEG, 
this might have led to inter-testing fatigue between subjects and controls i.e. patients 
are prone to more fatigue than controls. 
We have provided evidence that epilepsy patients show augmented photic drive 
response and that anti-epileptic medication reverses or decreases it. Investigation of the 
PDR offers yet another way to explore cortical hyper-excitability in epilepsy patients. 
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mfPOP responses were inversely related to the alpha band gain results and so may 
provide supplementary data on epilepsy status.  
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Chapter 5. 
Conclusion 
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We undertook the research in this thesis to establish the use of multifocal 
pupillographic objective perimetry (mfPOP) in two neurological disorders with 
many similarities epilepsy and migraine, we also explored the common phenomena 
of photosensitivity and cortical excitability that both disorders share. We 
accomplished our aim through three experimental chapters: the first examined 
migraine patients using protocols designed to stimulate melanopsin containing 
retinal ganglion cells, which are believed to play a role in exacerbating migraine 
headaches through light (Noseda et al., 2010). In the second chapter we shed light 
on pupillary changes in epilepsy patients and we incorporated 
electroencephalography (EEG) to examine the safety of mfPOP clinically and sub-
clinically in epilepsy subjects. In the third chapter again we used EEGs in epilepsy 
patients to explore a phenomena related to light stimulation, which is the alpha 
rhythm entrainment also known as the photic drive response. The conclusions of 
these three chapters can be summarised into three main categories, which are 1) 
photosensitivity and safety of the mfPOP device in neurological disorders; 2) 
cortical excitability in migraine and epilepsy and how they can be further explored 
using mfPOP; and 3) importance of mfPOP in neurological disorders. 
5.1.  Photosensitivity  
 
As we expect the mfPOP device will be widely available in the near future to test 
variety of patients, so its safety when used in disorders known to be associated with 
photosensitivity is of great importance. We have provided evidence that in both 
epilepsy and migraine patients the use of mfPOP was well tolerated and safe. We 
went beyond subjective safety measures in migraine patients and made the study a 
randomised and crossed over design, gave extended headache diaries, and used non-
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standard mfPOP protocols, in particular -the blue protocol- to specially target cells 
known to play a major role in the pathophysiology of that disorder and subsequently 
insure optimal tolerability and safety. Likewise in epilepsy patients we tested 
subjects with the mfPOP device concomitantly with ongoing EEG recording as an 
extra measure of subclinical safety. Rarely do we see such steps are taken in the 
process of approving a medical device before its wide use. This stemmed from the 
gap we felt during counselling these subjects before testing and our inability of 
guaranteeing their safety since scientific data were lacking. The literature would 
suggest that the small, asynchronous, stimuli of mfPOP would not induce visual 
distress (Wilkins, 1995), however this was untested. Standardised safety testing of 
photosensitive subjects whether suffering from headache or epilepsy should be 
implemented for all light emitting device as part of their routine approval. 
5.2.  Cortical excitability 
 
One of the many aspects that Migraine and epilepsy share is the phenomena of cortical 
hyper-excitability, which is critical for generating epileptic seizures, and has been 
demonstrated between migraine attacks. Hyper-excitability during a migraine attack is 
believed to transition to cortical spreading depression (CSD) rather than to the hyper-
synchronous activity that characterizes epilepsy. Our results have shown that this 
phenomena spread further to involve the pupillary response pathway which is mainly a 
subcortical pathway, these results are summarised in (Figure 1). In case of migraine 
patients we found decreased pupillary constriction to occur after a migraine attack and 
this effect slowly tapered off with time. Thus, we believe we were detecting a recovery 
from the cortical spreading depression seen during a migraine attack.  
142 
 
On the other hand patients classified as having generalised epilepsy showed 
exaggerated pupillary constriction interictally, when testing is carried out long after an 
attack this increase tended to normalise. Both these phenomena were reversed by using 
two different classes of medications known to alter cortical hyper-excitability namely 
triptans - which are selective serotonin 5 HT1 receptor agonists - in migraine subjects, 
and antiepileptic medications - predominantly voltage dependent Na channel inhibitors 
- in epilepsy patients.  These results lead us to speculate that our findings were mostly a 
reversal of a central effect of the primary disease rather than an effect of the 
medications on their own. 
In the view of changes in cerebral blood flow in migraine – as evident on apparent 
water diffusion co-efficient (ADC) on diffusion-weighted MRI during cortical 
spreading depression (CSD) (Smith et al., 2006, Umesh Rudrapatna et al., 2015)- and 
epilepsy (Diehl et al., 1998), - we strongly feel that coupling such a modality with 
mfPOP testing could yield a lot of information that will further elucidate whether these 
blood flow changes are also contributing to the pupillary response changes. 
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Figure 1. Summary of cortical excitability changes and how they correlated with 
pupillary response changes. (A) Chapter 1: Post migraine attacks, similar to the 
persistence of the cortical spreading depression a persistence subcortical depression 
was seen that may have affected the pupillary response pathway leading to more 
pupillary dilatation, as time progressed following the attack this dilatation normalises. 
(B) Chapter 2: inter-ictally in epilepsy patients and mainly post attacks, cortical hyper-
excitability was correlated with a subcortical hyper excitability of the pupillary 
response leading to exaggerated pupillary constriction, more so for generalised epilepsy 
than focal. (C) Chapter 3: Photic drive response (PDR) was exaggerated in epilepsy 
patients, and was associated with a suppressive effect on pupil responses at -0.21 dB of 
pupil response per 1 dB of PDR enhancement. PDR= photic drive response, LGN= 
lateral geniculate nucleus, TRN= thalamic reticular nucleus.  
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Based on our knowledge of the common involvement of the thalamus in the visual 
pathway (mainly the lateral geniculate nucleus), the generation of the alpha rhythm, and 
the generation of spike wave activity in epilepsy patients via the thalamocortical 
circuits (mainly through the thalamic reticular nucleus (TRN)), we went further to study 
the photic drive response (PDR) - which again was used as a marker of cortical 
excitability - in epilepsy patients where we defined an alpha-band gain. We measured it 
in both subjects and controls and found the alpha-band gain amplitude was more 
pronounced in epilepsy patients than normal controls, and again these changes were 
attenuated by the use of anti-epileptic medications. Interestingly the increase in the 
alpha-band gain amplitude had an inverse relation to the pupillary constriction 
amplitude. This may be a protective mechanism by the brain to decrease light entry 
through the pupils in cases of exaggerated cortical excitability. 
All these results are an indication that along with transcranial magnetic stimulation, 
electroencephalography, and functional MRI, mfPOP is a useful device to study cortical 
hyper excitability and how it dynamically changes in disorders like epilepsy and 
migraine.  
5.3.  Importance of mfPOP as a perimetry device 
in neurology patients 
 
In addition to shedding the light on the underlying pathophysiology of cortical 
excitability and how the pupillary response is modulated (as seen above) when the 
mfPOP device was used in migraine patients it was capable of mapping visual field 
scotomas. They were found peripherally and concentrically located, changing with 
time, decreasing with time following attacks, and decreasing with the use of medication 
namely triptans. Not only were these results consistent with results obtained with other 
145 
 
methods of perimetry, they also contributed to our understanding of the source 
generator of these scotomas. The source of migraine scotomas has been long debated in 
the literature. Our results here suggested that both cortical and subcortical visual 
processing anomalies occur in migraine. MfPOP visual field results are obtained 
through the pupillary response with less influence from the cortex – particularly with 
the long blue stimuli used (Carle et al., 2015) - thus giving evidence that subcortical 
structures do contribute to the source of these scotomas.  
So far we have shown results of the application of mfPOP in two neurological disorders 
namely migraine headaches and epilepsy. We have also investigated its use in previous 
work on multiple sclerosis (Ali et al., 2014). Ongoing work is exploring its use in 
detecting abnormalities in stroke and pituitary tumour patients.  
Neurology patients are known to have multiple comorbidities in the cognitive and 
motor domains, these limitations make standard perimetry testing difficult in terms of 
cooperativity and tolerability. In addition the subjective results of other perimetry 
methods may be affected by cognitive issues affecting these patients. Therefore the 
development of a test that is rapid, objective, and does not require motor cooperation in 
the form of pushing buttons, is of great importance to these patients. These factors were 
taken into account during the development of the mfPOP device. We hope in the near 
future to establish the mfPOP device as the standard for perimetry in neurology 
patients. 
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